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 Zusammenfassung 
 
X-Chromosom-Inaktivierung ist der Vorgang, bei dem die unterschiedlichen 
Genmengen zwischen weiblichen (XX) und männlichen (XY) Säugern 
kompensiert wird. Bei weiblichen Säugetieren wird während der frühen 
Entwicklung ein X Chromosom transkriptionell abgeschalten und bildet den 
sogenannten ´Barr body´. Dieser Inaktivierungsvorgang wird von der Xist RNA 
initiiert, welche sich über das gesamte Chromosom ausbreitet von dem sie 
transkribiert wird. Während der frühen embryonalen Entwicklung ist Xist 
notwendig für die Initiierungsphase des Inaktivierungsvorganges. Später in der 
Differenzierung, in der sogenannten  ´Aufrechterhaltungsphase´, wird der 
inaktive Status des Chromosoms irreversibel und unabhängig von der 
Expression von Xist. Obwohl bereits einige Faktoren, die durch die Expression 
von Xist rekrutiert werden, identifiziert wurden, ist der Mechanismus, der den 
Übergang von der Initiierungs- zur Aufrechterhaltungsphase einleitet, noch nicht 
geklärt.  
In der Initiierungsphase werden Histone modifiziert, während in der 
Aufrechterhaltungsphase Proteine, wie Saf-A, Ash2 und macroH2A rekrutiert 
werden und Histon H4 hypacetyliert wird. Die Rekrutierung von Saf-A, Ash2 und 
macroH2A und die Modifizierung von Histonen sind abhängig von der Expression 
von Xist, benötigen jedoch des weiteren das sogenannte ´Chomosomale 
Gedächtnis´, welches eine spezifische chromosomale Veränderung am X 
Chromosom darstellt.  
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Diese Veränderung, welche während der frühen ES Differenzierung am X-
Chromosom etabliert wird, ist bis jetzt auf molekularer Ebene ungeklärt. 
Deacetylierung von Histon H4 besitzt Eigenschaften, die mit jenen des 
´Chromosomalen Gedächtnisses´ korrelieren und  könnte daher eine 
Komponente des ´Gedächtnisses´ darstellen. 
 Im ersten Teil dieser Arbeit wurde die Deacetylierung von Histon H4 als 
potentielle Kandidatin für die molekulare Veränderung des `Chromosomalen 
Gedächtnisses´ untersucht. Hierbei wurden die Effekte auf das ´chromosomale 
Gedächtnis´ nach chemischer Inhibierung der Histon Deacetylasen untersucht. 
Die Resultate dieser Studie deuten darauf hin, dass die Klasse III der Histon 
Deacetylasen potentiell mit der Bildung des ´Chromosomalen Gedächtnisses´ 
involviert ist.  
 Im zweiten Teil dieser Arbeit wurde ein biochemischer Ansatz für die 
Identifizierung von Faktoren, welche in der Initiierungsphase durch Xist 
rekrutieren, erforscht. 
 Das Ausbreiten der Xist RNA über das gesamte X Chromosom in der 
Initiierungsphase vermittelt eine transkriptionelle Inaktivierung des Chromatins, 
ist aber alleine nicht ausreichend für die Repression der Gene. Die Faktoren, 
welche mit Xist kooperieren um das anfängliche Stilllegen der Gene zu 
bewerkstelligen, sind bis dato nicht bekannt.  
 In unserer Studie haben wir ein Verfahren für eine biochemische 
Fraktionierung der nuklearen Matrix, welche bekanntermaßen die Xist RNA 
beinhaltet, entwickelt. Die Untersuchung dieser Fraktion machte es möglich 
Proteine zu detektieren, die sich durch X-Inaktivierung anreichern.   
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 Eine massenspektrometrische Analyse dieser Proteinproben identifizierte 
die  Anreicherung von Trim28 in ES-Zellen durch die Expression von Xist. Trim28 
spielt eine Rolle beim Stilllegen retroviraler Gene in ES-Zellen (Wolf und Goff, 
2007). Daher, deuten die vorläufigen Ergebnisse dieser Arbeit darauf hin, dass 
Trim28 einen interessanten Kandidaten für den Mechanismus der X-Inaktivierung 
darstellt. Weitere Studien, wie genetische Ansätze, werden notwendig sein, um  
das Involvieren von Trim28 in der X-Chromosom-Inaktivierung zu testen. 
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 Summary 
 
X chromosome inactivation is the process that compensates the different gene 
dosages between females (XX) and males (XY) in mammals. During early 
mammalian development one X chromosome becomes transcriptionally silent, 
which leads to the formation of the so called Barr body. This silencing process is 
triggered by Xist RNA, which initially spreads over one chromosome from which it 
is transcribed. Xist is required for initiation of X inactivation early in development 
during the so called initiation phase. Later in differentiation silencing becomes 
irreversible and independent of Xist during the maintenance phase. Albeit, 
several factors have been identified that are recruited by Xist in the maintenance 
phase, the mechanism for the transition from initiation to maintenance of X 
inactivation is presently unknown. During the process of X inactivation, histones 
are modified in the initiation phase and the recruitment of Saf-A, Ash2, macroH2A 
and hypoacetylated histone H4 mark the maintenance phase. The recruitment of 
Saf-A, Ash2, macroH2A and histone modifications are dependent on Xist 
expression and in differentiation a molecular change on the X chromosome is 
triggered that has been termed ´chromosomal memory´. The molecular basis of 
this chromosomal change, which is established early in ES differentiation, is 
presently unknown. Deacetylation of histone H4 represents a chromatin feature 
that correlated with memory and could be a component of its mechanism. 
 In the first part of this work deacetylation of histone H4 was investigated as 
chromatin feature that correlates with memory. Its role as a component of the 
memory mechanism was tested using chemical inhibition of histone 
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deacetylation. The results of this study suggest that class III histone 
deacetylases could potentially be involved in the formation of memory.  
 In the second part of this work a biochemical approach was explored for the 
identification of factors that are recruited by Xist for the initiation of X inactivation. 
During the process of X inactivation, initial spreading of Xist RNA mediates the 
formation of silent chromatin, but is not sufficient for gene repression. The factors 
that cooperate with Xist the initial establishment of silent chromatin are presently 
unknown. In our study, we established a biochemical fractionation procedure of 
the nuclear matrix fraction, which is known to contain Xist RNA, to detect proteins 
that become enriched in the matrix fraction upon X inactivation. Mass 
spectrometric analysis of protein samples identified an enrichment of Trim28 in 
ES cells upon Xist expression. Trim28 has been implicated in retroviral silencing 
in ES cells (Wolf and Goff, 2007). Thus, the preliminary findings of this work 
suggest Trim28 as an interesting candidate for the mechanism of X chromosome 
silencing. Future work including genetic studies will be required to test a potential 
involvement of Trim28 in X inactivation. 
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Dosage compensation systems 
 
Different sex determination systems have evolved throughout the animal 
kingdom. Environmental sex determination (such as systems based on ambient 
temperature) and genetic sex determination are used by closely related species. 
Sex determination by sex chromosomes can be observed in worms, insects and 
vertebrates. One of the sex chromosomes has become structurally modified and 
limited to one sex. The other sex chromosome has remained structurally 
unchanged. Depending on the species, the structurally modified chromosome is 
transmitted from males to sons (Y chromosome) or from females to daughters (W 
chromosome). Therefore either males (XY) or females (ZW) can be 
heterogametic. The unmodified chromosome is present in two doses in the 
homogametic sex, which results in an inequality in the dosage of the genes, 
present on the X or Z chromosomes in males and females. Many of these genes 
are equally important for the development and maintenance of both males and 
females. Therefore different gene dosages of both sexes would lead to a 
variation in gene expression levels, which might result in differential selection 
between the sexes. To compensate for differences in the dosage of X-linked or 
W-linked genes between the sexes, mechanisms have evolved to prevent such 
inequalities. 
 The mechanisms that are employed to achieve dosage compensation of 
gene expression of X or W linked gene products are remarkably different 
throughout the animal kingdom.  The phenomenon of dosage compensation was 
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discovered in Drosophila by Herman Muller more than 70 years ago. To date, 
dosage compensation mechanisms have been extensively studied in three very 
distantly related species: mammals, Caenorhabditis elegans and Drosophila 
melanogaster. These organisms achieve the transcriptional regulation leading to 
equal gene expression in different ways. In Drosophila the level of transcription of 
the single male X chromosome is increased 2-fold to equalize gene expression of 
XX females (Akhtar, 2003). C. elegans decreases the level of transcription of the 
two doses of X-linked genes in hermaphrodites to achieve dosage compensation 
to X0 males (Meyer, 2000). In mammals the two X chromosomes are treated 
differently in female cells: The inactivation of one of the two female X 
chromosomes compensates the dosage of X-linked genes between the sexes.  
The study of dosage compensation provides a unique window into a variety of 
fundamental mechanisms of transcriptional regulation.  
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X chromosome inactivation compensates X 
chromosome gene dosage in mammals 
 
 
X chromosome inactivation 
Several observations provided the basis for Mary F. Lyon´s pioneering theory of 
X chromosome inactivation in mammals (Lyon, 1961): The observation of a 
dense staining nuclear structure in neuronal nuclei of female cats in 1949 was 
the first evidence for mammalian X chromosome inactivation (Barr and Bertram, 
1949). Later it was discovered that this ´sex chromatin body´ or Barr body, which 
was observed in nuclei of somatic cells of females, corresponds to an X 
chromosome (Ohno and Hauschka, 1960). This observation laid the cornerstone 
of the study of dosage compensation in mammals, which demonstrated that one 
of the two X chromosomes in female cells is randomly inactivated through 
transcriptional silencing thereby equalizing the expression of X-linked genes 
between XX females and XY males (Lyon, 1961). Further, it was demonstrated 
that female mice showed a spotted phenotype due to a translocation of an 
autosomal coat colour gene to the X chromosome (Russell, 1963). Detailed 
analysis of X; A translocations resulted in the identification of a cis-acting DNA 
element regulating X chromosome inactivation. This element was named the X 
chromosome inactivation centre (Xic). The Xic was defined as a 700 kb – 1200 
kb region using translocations involving the X chromosome that were able to 
induce silencing of autosomal coat colour genes. When translocated to an 
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autosome the Xic triggered an ectopic inactivation event (Rastan, 1983; Rastan 
and Robertson, 1985). A more recent study identified the localization of the Xic to 
(Brown et al., 1989). This facilitated the discovery of a gene encoding a 
nontranslated RNA, X inactive-specific transcript or XIST that is transcribed only 
by the inactive chromosome (Brown et al., 1991a; Brown et al., 1991b; Brown, 
1991). The observation that XIST is a noncoding RNA, which localizes to the 
chromatin of inactive X (Brown et al., 1992), suggested that it might be involved 
in the silencing process. The Xic contains the genetic information for counting, 
choice and the silencing process itself. Counting is a process whereby the X;A 
ratio is measured and only one single X chromosome per diploid autosome set 
remains active. The Xic elements required for counting were mapped to cis 
acting sequence lying 5´ and 3´ to Xist (Augui et al., 2007; Herzing et al., 1997). 
Deletion of 65 kb in the region 3´ to the Xist gene leads to inappropriate X 
chromosome inactivation even in male cells with a single X (Morey et al., 2004). 
This demonstrates that counting is achieved only by the Xic region. The choice of 
the X chromosome that will undergo X inactivation is influenced by multiple 
elements spreading across the Xic region. The Xic contains 12 transcription 
units, seven of which are not involved in X inactivation (Xptc, Cnbp2, Tsx, Chic1, 
Cdx4, Nap1/2 and Ppnx). The Xic is very characteristic in its high abundance of 
genes encoding non-coding RNAs (Xist, Tsix, Ftx, Jpx) (Rougeulle and Avner, 
2003).  
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Figure 1: Transcriptional map of the X inactivation centre (Xic) 
Genes shown in red produce non-coding transcripts and genes shown in blue produce protein-
coding transcripts and have no known Xic related function. Regions shown in brown show 
elements involved in counting and choice. 
 
 
 
 The Xist gene is required for X chromosome inactivation 
 
The fist gene, which was mapped to the Xic was the Xist gene. It encodes a 17 
kb long non-coding spliced RNA that is exclusively expressed from the inactive X 
chromosome (Borsani et al., 1991; Brockdorff et al., 1991; Brown et al., 1991a; 
Brown et al., 1991b). 
 Deletions at the Xist locus showed that this gene is absolutely required for 
the initiation of X inactivation in cis (Marahrens et al., 1997; Penny et al., 1996). 
Xist is expressed at low levels in undifferentiated female ES cells. In cells that 
contain more than one Xic, Xist expression is upregulated on the future inactive 
X chromosome after one to two days of ES differentiation. Xist RNA physically 
interacts with the chromatin in cis and covers the entire chromosome from which 
it is transcribed, suggesting that it could serve as a recruitment factor for 
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additional molecules that are essential for X chromosome inactivation (Clemson 
et al., 1996; Wutz, 2003). Transcriptional silencing occurs between one or two 
cell cycles after RNA coating (Wutz and Jaenisch, 2000). This indicates that Xist 
is directly responsible for mediating gene silencing. Xist expression at later 
stages of differentiation no longer causes silencing anymore. Thus, its function is 
developmentally restricted (Wutz and Jaenisch, 2000). Chromosomal coating of 
Xist RNA does not depend on specifically on features of the X chromosome as 
Xist also interacts with chromatin in cis when expressed from an autosome (Wutz 
and Jaenisch, 2000). Recent studies showed that Xist co-localizes with the 
nuclear matrix protein scaffold attachment factor A (Saf-A) (Fackelmayer, 2005; 
Helbig and Fackelmayer, 2003), indicating that the nuclear matrix could 
contribute to Xist localization to the X chromosome. Xist localization is cell cycle 
dependent (Clemson et al., 1996). In mouse cells, Xist detaches from the Xi at 
the transition from metaphase to anaphase and is coating the same chromosome 
when the cells re-enters G1 phase.  
 Further observations showed that the localization along the length of the X 
chromosome and the silencing ability of Xist RNA are functionally separable 
(Wutz et al., 2002). 
 Identification of factors that bind to the different functional regions of the Xist 
RNA will provide more insight into the mechanism of silencing. 
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The repeat- A motif at the 5´end is essential for gene silencing 
 
First cloning and sequencing studies of the mouse Xist gene revealed that the 
full-length 15 kb transcript contains no significant conserved open reading frame 
(ORF) (Brockdorff et al., 1992). Further sequencing analysis of the Xist gene 
revealed significant conservation over five short regions and Xist specific tandem 
repeats. However, the Xist genes of different mammals show low overall 
sequence conservation (Nesterova et al., 2001). Experimental evidence of the 
functionality of direct repeat sequences were observed by deletion analysis of 
mouse Xist RNA (Wutz et al., 2002). Deletion of the highly conserved sequence 
motif at the 5´end, the so called ´A-repeat´, resulted in a mutant RNA that is 
unable to induce gene silencing without affecting Xist localization to chromatin 
(Wutz et al., 2002). Further it was shown that macroH2A1 localizes to the X 
chromosome independently of silencing.  This indicates that the ´A-repeat´ is 
essential for the initiation of XCI, but is not required for recruitment of factors to 
the inactive X chromosome. In contrast to the defined domain, that is required for 
silencing, regions for Xist localization are scattered throughout Xist and are 
functional redundant (Wutz et al., 2002).   
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A shift from reversible to irreversible gene silencing  
 
The development of an inducible Xist expression system in male ES cells made it 
possible to experimentally control the initiation of chromosome-wide silencing in 
ES cell differentiation. In this system the transactivator for the TetON system is 
fused to a nuclear localization signal (nlsrtTA) and further knocked into the 
Rosa26 locus on chromosome 6 by homologous recombination (Gossen et al., 
1995; Wutz and Jaenisch, 2000). Addition of doxycycline induces the expression 
of Xist cDNA transgene (Wutz and Jaenisch, 2000). In undifferentiated ES cells 
induction of Xist expression causes efficient, but reversible gene silencing. 
Silencing is restricted to the chromosome containing the Xist transgene and 
requires continuous Xist expression. After 48 hours of ES cell differentiation an 
epigenetic transition occurs on the chromosome that makes chromatin 
irresponsive to Xist. One cell division later, after passing a ´critical window´ of 
XCI at 72 hrs of differentiation, silencing becomes irreversible and is maintained 
by redundant mechanisms even in the absence of Xist expression. 
These experiments indicated that during the initiation phase of X inactivation, Xist 
causes efficient, but reversible gene silencing. Xist is no longer required for 
maintenance of the inactive state. Upon differentiation a transition to a chromatin 
state occurs that establishes irreversible gene silencing and maintenance of XCI 
(Wutz and Jaenisch, 2000). 
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X inactivation is a multi-step process  
 
X chromosome inactivation is a developmentally regulated process. It can be 
recapitulated in female ES cells. Studying ES cell differentiation provided insight 
into the epigenetic events during X chromosome inactivation. XCI starts with the 
accumulation of Xist along the entire future inactive X chromosome and the 
exclusion of the transcription machinery from the Xi chromosome territory. RNA 
polymerase II, splicing factors and nascent transcripts are absent from the Xist 
covered chromosome. Subsequently, Polycomb repressor complex 1 (PRC1) 
and 2 (PRC2) are recruited to the inactive X and mediate histone modifications 
such as ubiquitinylation of histone H2A lysine 119 and tri-methylation of histone 
H3 lysine 27 (H3K27me3). During this initiation phase of XCI Xist triggers 
silencing. If cell differentiation progresses histone macro H2A, Saf-A and Ash2 
becomes enriched on the Xi. Further, histone H4 becomes hypoacetylated. 
During this maintenance phase Xist is not required for the silent state. 
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Figure 2: X chromosome silencing is a multistep process 
Initially, Xist RNA spreads over the whole chromosome from which it is transcribed. Xist RNA 
accumulation is followed by recruitment of Polycomb repressor complex 1 and 2 which mediate 
histone modifications as trimethylation of H3K27. As cell differentiation progresses histone H4 
becomes hypoacetylated and the proteins SafA, Ash2, and macroH2A recruit to the inactive X. 
This silencing process can be divided in 2 phases. The initiation phase, which is reversible and 
Xist dependent followed by the maintenance phase which is irreversible and independent of Xist 
expression.  
 
 
 
A chromosomal memory is triggered by Xist in ES differentiation 
 
Xist is able to induce chromosome-wide silencing at early timepoints in ES cell 
differentiation. During differentiation Xist loses its potential for initiation of gene 
silencing. In somatic cells such as embryonic fibroblasts forced expression of Xist 
does not trigger silencing (Wutz and Jaenisch, 2000). During cellular differentiation 
silencing of the inactive X becomes irreversible and independent of Xist 
(Csankovszki et al., 2001; Marahrens et al., 1998; Penny et al., 1996). Thus, X 
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inactivation can be separated into an initiation phase, when initiation of silencing 
depends on Xist, and a maintenance phase that is independent of Xist. 
 The mechanism that underlies the transition to the maintenance phase and 
the factors that are involved in this process are presently unknown. During the 
process of X inactivation, the recruitment of a variety of different factors and 
posttranslational modifications are involved. Early in ES cell differentiation Xist 
recruits the Polycomb group complex 2 to the inactive X chromosome mediating 
tri-methylation of histone H3 lysine 27 (H3K27me3). Recruitment of PcG 
complexes requires Xist RNA. Thus, the PcG associated histone modifications 
are reversible and are lost when Xist expression is disrupted. Turning off Xist 
during maintenance phase resulted in low levels of H3K27me3 (Kohlmaier et al., 
2004). Xist is not sufficient for PcG recruitment in differentiated cells. The 
maintenance of efficient H3K27me3 late in ES cell differentiation is dependent on 
a ´chromosomal memory´. Studying H3K27me3 in male ES cells carrying an 
inducible Xist cDNA transgene showed that Xist expression in an early time 
window in ES cell differentiation is essential for efficient PcG recruitment later in 
differentiation. H3K27me3 was detected when Xist was induced before 3 days of 
differentiation. However, induction of Xist from later timepoints led to inefficient 
recruitment of PcG complexes and histone modifications. 
 These studies also revealed that continuous expression of Xist was not 
required for efficient recruitment in differentiated cells. When Xist was induced 
early, efficient H3K27me3 could be established in differentiated cells when Xist 
was reexpressed even after a period of no Xist expression. Since continuous Xist 
expression and continuous H3K27me3 were not required it was proposed that a 
memory had been established after 3 days of differentiation that could be 
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maintained independent of Xist (Kohlmaier et al., 2004). This study indicates that 
a molecular change on the X chromosome, termed the chromosomal memory, 
which is established upon early Xist expression and stays independent of Xist 
during maintenance phase correlates with the transition to the maintenance 
phase (Kohlmaier et al., 2004).  
 Previously, it has been shown that the recruitment of the TrxG protein 
Ash2l, Saf-A and macroH2A occurs concurrently with memory imposition in ES 
cell differentiation. Similar to tri-methylation of H3K27, Xist expression during 
early differentiation also regulates efficient recruitment of Saf-A, Ash2 and 
macroH2A (Pullirsch 2008). 
 
 
Histone deacetylation as a potential mechanism for 
chromosomal memory 
 
The recruitment of Saf-A, Ash2, macroH2A and histone modifications such as 
H3K27me3 and H2AK119ub1 are dependent on Xist expression and in 
differentiated cells require a molecular change on the X chromosome. This 
chromosomal change is established by Xist expression during and early 
timewindow in ES cell differentiation and is called the ´chromosomal memory´. 
Presently, the molecular basis of this X chromosomal memory is unknown. 
 Notably, it was shown that in differentiated cells Xist mediated H2A 
ubiquitination is regulated by a memory but is not dependent on gene silencing 
(Schoeftner et al., 2006). Further studies demonstrated that Saf-A, Ash2 and 
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macroH2A are recruited to the X chromosome upon early Xist expression in 
differentiated ES cells that lack the A repeat responsible for silencing (Pullirsch, 
2008). These studies indicate that the establishment of memory is independent of 
gene silencing and that the mechanism of memory is different from the formation 
of a silent heterochromatic X chromosome. 
 Conditional deletion of Xist RNA in mouse embryonic fibroblasts 
demonstrated that in the absence of Xist, hypoacetylation on histone H4 is 
maintained on the inactive X chromosome (Csankovszki et al., 1999). Analysis 
on the timing of histone H4 hypoacetylation showed that a hypoacetylated X 
chromosome was established by Xist in ES cells after 3 days of differentiation 
(Chaumeil et al., 2002; Keohane et al., 1996). Remarkably, a hypoacetylated X 
chromosome was detected in ES cells expressing a silencing deficient Xist after 
3 days of differentiation, which was stably maintained after Xist was turned off on 
day 4 of differentiation (Pullirsch, 2007). These data demonstrate that 
hypoacetylation of histone H4 occurs at the time when memory is established 
and can be maintained independent of Xist and gene repression, indicating a 
correlation of H4 hypoacetylation with memory in X inactivation. 
 Histone deacetylases (HDACs), which catalyze the removal of acetyl 
groups from the N-terminal tails of histones, can be divided phylogenetically into 
three classes based on their homology to Saccharomyces cerevisiae HDACs: 
Rpd3 (class I), Hda1 (class II) and Sir2 (class III). Class I and II both require the 
presence of a zinc ion for hydrolysis of the acetyl group. Upon deacetylation both 
release the acetyl group in the form of acetate. In contrast, Sir2 requires the 
presence of the metabolic cofactor NAD+ for deacetylation. The acetyl group is 
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removed from the histone by an ADP-ribosyl transferase reaction, which transfers 
the acetyl group to ADP ribose (Ekwall, 2005).  
 
 
Figure 3: Sirt2 deacetylation 
In the presence of an acetylated lysine (K) 
substrate, Sir2 catabolises the NAD 
molecule into activated ADP-ribose and 
nicotinamide. The latter product is 
released. The enzyme catalyses the 
transfer of the acetyl group to ADP-ribose, resulting in a deacetylated substrate and a                   
novel compound, O-acetyl-ADP ribose (AAR), as final product. 
 
S. cerevisiae Sir2 is involved in the epigenetic silencing of three main loci in 
budding yeast: mating type loci, telomeres and nucleolar rDNA tandem repeats 
(Guarente, 1999). Sir2 hypoacetylates lysine 16 on the N-terminal tails of histone 4, 
which is a mark of Sir2 silencing (Guarente, 1999; Robyr et al., 2002). The product 
of the deacetylation reaction is O-acetyl-ADP ribose, which is probably required for 
spreading of the Sir complex on chromatin since it changes the conformation of 
Sir3 and promotes its binding to Sir2/Sir4 dimers in vitro (Liou et al., 2005). 
Interestingly, it was observed in mammalian systems, that O-acetyl-ADP ribose can 
bind to macroH2A which is recruited to the inactive X chromosome in maintenance 
phase (Kustatscher et al., 2005). 
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Factors involved in the initiation phase of X inactivation 
 
Several early alterations in chromatin structure occur during the initiation phase 
of X inactivation. The expression of Xist RNA triggers these epigenetic changes. 
Asynchronous replication of the two X chromosomes in female cells is observed 
early after Xist has covered the chromosome. This contrasts with the behaviour 
of homologous autosomes, which replicate at the same time in S-phase 
(Morishima et al., 1962). Late replication is a classic marker for the silent X 
chromosome (Csankovszki et al., 2001; Takagi et al., 1982). 
 Several recent studies have focused on the action of Xist early in 
differentiation and identified the loss of euchromatin-associated histone 
modifications such as acetylation of histone H3 lysine 9 (H3K9Ac) and di- and tri-
methylation of histone H3 lysine 4 (H3K4me2, H3K4me3) (Chaumeil et al., 2002; 
Heard et al., 2001; Okamoto et al., 2004). However, it is not clear if this early 
disappearance of histone marks is a passive effect of replication or an active 
removal by enzymatic or proteolytic factors. 
Immediately following these changes, polycomb group proteins appear on the 
Xist coated chromosome mediating histone modifications such as dimethylation 
of histone H3 lysine 9, monomethylation of histone H4 lysine 20 and 
ubiquitination of histone H2A (de Napoles et al., 2004; Heard et al., 2001; 
Kohlmaier et al., 2004; Plath et al., 2003; Silva et al., 2003). Global H4 
hypoacetylation occurs shortly afterwards and marks the maintenance phase of 
X inactivation.  
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The first discovery of Polycomb group proteins as important silencing factors was 
made in Drosophila (Simon and Tamkun, 2002). Two large Polycomb repressive 
complexes (PRCs) were identified in mammals: PRC2 is thought to be involved 
in the initial maintenance of the repressed states and the PRC1 complex is 
thought to act subsequently to, and synergistically with PRC2.  The role of the 
histone modifications catalyzed by PRC1 and PRC2 is presently unknown. The 
histone methyl-transferase PRSet7 was suggested to mediate H4K20me1. G9a 
was suggested as a likely candidate for H3K9 dimethylation, although no 
alteration on the inactive X chromosome was observed in G9a-knock-out mice 
embryos (Ohhata et al., 2004). The establishment of H3K27me3 and H4K20me1 
was observed in ES cells expressing a silencing-deficient Xist RNA. This 
indicates that histone modifications, which mark the silent chromatin, are not 
sufficient to initiate gene silencing during X chromosome inactivation. Possibly, 
the initiation and maintenance of gene silencing requires the recruitment of an 
unknown factor to the A-repeat of Xist, which is responsible for silencing. Yet, the 
factors directly interacting with Xist RNA are not known. Identifying new 
components of the inactive X chromosome holds promise for unravelling novel 
pathways for epigenetic gene silencing. 
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Project 1: Investigation of the role of histone 
deacetylation in establishing a chromosomal memory 
during X inactivation 
 
 
Introduction 
 
 Previously, it has been shown that Xist expression during early differentiation 
regulated the efficiency recruitment of Saf-A and Ash2 as well as other proteins 
and modifications to the Xi in differentiated cells (Pullirsch 2008). Since 
continuous Xist expression was not required a memory had apparently been 
established on the chromosome at a specific time point, after 3 days of 
differentiation that could be maintained independent of Xist. However, neither 
Saf-A, Ash2 nor other proteins, which mark the Xi in differentiated cells, were 
maintained when Xist expression was turned off. This raised the question of the 
molecular basis for memory. Notably, establishment of memory has been 
observed independent of gene silencing, when recruitment of Polycomb 
complexes was used as readout (Leeb and Wutz, 2007; Schoeftner et al., 2006). 
This suggested that the mechanism of memory is different from the formation of 
a heterochromatic inactive X chromosome. 
 Global hypoacetylation of histone H4 had been previously shown to be 
established by Xist at the time of memory imposition independent of gene 
repression (Pullirsch et al., 2008) and was further maintained independent of Xist 
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on the silent Xi (Csankovszky et al., 1999; Pullirsch et al., 2008). Therefore, 
deacetylation of histone H4 represented a chromatin feature that correlated with 
memory and could be a component of its mechanism. 
 If histone H4 hypoacetylation were a critical component of memory, 
acetylation of histone H4 would be predicted to interfere with the recruitment of 
memory. Consequently, impaired memory could be readout by failure to recruit 
factors to the Xi. We attempted to test this prediction experimentally by blocking 
histone deacetylases using chemical inhibitors. 
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Results 
 
Recruitment of Saf-A and Ash2 protein to the inactive X by Xist 
expression 
 
In order to characterize the timing of Ash2 and Saf-A recruitment in X inactivation 
we used an inducible Xist expression system in mouse ES cells, which 
recapitulates the initiation and maintenance of chromosome-wide silencing (Wutz 
and Jaenisch, 2000). For this we used ∆sxSafA:hrGFP male ES cells with an 
inducible promoter at the transcription start of the endogenous Xist gene, 
carrying a deletion of the 5´end including the so called repeat A and a Saf-
A:hrGFP transgene (Wutz et al., 2002);(Pullirsch et al, 2008). Xist lacking repeat 
A localizes to the X chromosome, forms a compartment deficient in RNA 
polymerase II, recruits PcG proteins and establishes histone modifications 
(Chaumeil et al., 2006; Kohlmaier et al., 2004; Plath et al., 2003; Schoeftner et 
al., 2006). Expression of the mutant Xist RNA by addition of doxycycline does not 
result in gene repression avoiding thereby cell death due to inactivation of the 
single X chromosome of the male ES cells.  
 We induced differentiation with retinoic acid in ∆sxSafA:hrGFP  male ES cells 
and at the same time expression of Xist by doxycycline. 
 To determine the timing of Saf-A recruitment by Xist the number of hrGFP 
foci were counted during differentiation of sxSafA:hrGFP  male ES cells.  After 2 days 
of differentiation 10% of the cells showed focal SafA-hrGFP signals (Figure 4A). 
In contrast, we did not detect focal enrichment of the Saf-A-hrGFP protein after 
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induction of Xist expression in undifferentiated ∆sxSafA:hrGFP  ES cells. During 
further differentiation, the percentage of cells showing Saf-A foci increased to 
48% between day 3 and 4. At the final time point (day 5) 65% of the cells showed 
focal Saf-A signals (Fig 4A). 
 In parallel cultures we detected Ash2 by immunofluorescence staining (Fig 
4B). Ash2 recruitment was first observed on day 2 of differentiation with a 
significant rise in the number of cells showing Ash2 focal staining between day 3 
and 4. This showed that recruitment of Ash2 obeyed similar kinetics as Saf-A. 
Ash2 immunofluorescence staining of ∆sxSafA:hrGFP  ES cells was performed using 
a commercial antibody. In order to verify its specificity, we established 36.11. ES 
clones carrying a doxycycline inducible Ash2L RNAi construct and analyzed 
Ash2 protein levels and Ash2 recruitment upon doxycycline treatment (Figure 5).  
For this, 36.11 Ash2L RNAi clones 1 and 4 were differentiated with retinoic acid 
and RNAi was induced with doxycycline for 2 days. The effect of Ash2l RNAi was 
confirmed in two independent clones by Northern analysis (Figure 5B). A strong 
reduction of Ash2l transcript was observed after induction of RNAi by the addition 
of doxycycline. Western blot analysis showed a severe reduction of Ash2l protein 
in RNAi induced cells compared to control cells cultivated without doxycycline 
(Figure 5A). To further investigate Ash2l antibody specificity, Ash2l 
immunofluorescence staining was performed, which showed a clear reduction of 
cells containing Ash2l foci upon RNAi induction (Figure 5C). Since both 
immunofluorescence staining as well as western blot analysis showed a clear 
effect upon Ash2 RNAi induction, we conclude that the Ash2 antibody was 
specific. 
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Figure 4: Recruitment of Saf-A and Ash2 in ∆sxSafA:hrGFP  ES cells 
An analysis of Saf-A (A) and Ash2 (B) recruitment by Xist in undifferentiated 
∆sxSafA:hrGFP ES cells and after 1, 2, 3, 4 and 5 days of differentiation in the 
presence of doxycycline is shown. The percentage of cells showing focal 
enrichment is given (n=100). 
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 Figure 5: Specificity of the Ash2l antibody staining of the Xi 
The effect of RNAi from 36 ES cells carrying inducible Ash2l RNAi constructs was confirmed by 
Northern analysis. Multiple clones are shown for two independent Ash2l constructs . Reduction of 
the Ash2l transcripts is observed upon induction of RNAi with doxycycline (+dox). Gapdh is a loading 
control. Puro is repressed by Xist induction with doxycycline in 36 ES cells (5A). Western analysis of 
Ash2l in extracts from 36 ES cells carrying inducible Ash2l RNAi constructs. Induction of RNAi by 
doxycycline (+dox) results in reduced amount of Ash2l protein (5B). Two independent RNAi 
constructs (#1 and #4) were analysed.. Immunofluorescence staining in differentiated 36 ES cells 
carrying inducible Xist and Ash2l RNAi constructs. Fewer and weaker Ash2l foci are observed in 
Ash2l RNAi clones compared to controls containing unrelated RNAi constructs (two independent 
constructs #1 and #2 are shown each). Statistical analysis of the number of cells showing Ash2l foci 
is given on the right. Ash2l RNAi does not affect Xist expression (5C). 
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Reduction of cells containing Saf-A foci upon inhibition of 
sirtuins early in ES differentiation 
 
For assessing the effect of histone deacetylase (HDAC) inhibitors on memory 
establishment ∆sxSafA:hrGFP ES cells were differentiated for seven days with 
retinoic acid in the presence of doxycycline to induce Xist expression. Histone 
deacetylase inhibitors against class I, II and III of histone deacetylases were 
added from day 1 to day 5 of differentiation in parallel cultures. At day 7 of 
differentiation Saf-A recruitment and Xist localization were analyzed. 
 Control cultures were cultivated in the absence of inhibitors and served as a 
reference for memory recruitment. Induction of Xist late in differentiation, when 
memory cannot be recruited, served as a negative control (Figure 6). 
 
 
Figure 6: Time course of the experimental setup 
Silencing deficient Xist was continuously induced in cultures treated from day 1 
to day 5 with HDAC inhibitors. Both positive and negative controls were 
cultivated without inhibitors. Xist was induced throughout differentiation in the 
positive control and from day 5 on in the negative control.  
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As expected positive as well as negative control cells show Xist localization in the 
vast majority of cells. Since Xist was not induced during memory formation in the 
negative control, the recruitment of the Saf-A protein, which is dependent on 
memory, is severely reduced compared to the positive control. 
 TSA and MS275 treated cells show a severe reduction of cells containing 
Saf-A foci. However, indirect effects due to inhibition of deacetylases could not 
be ruled out as disperse Xist clusters were observed, suggesting that these 
HDAC inhibitors had led to delocalization of Xist (Figure 7). 
 To further investigate whether DNA methylation could play a role in memory 
formation, we included RG108, a DNA methylation inhibitor, in our study. 
Addition of RG108 during the first 5 days of differention of ∆sxSafA:hrGFP ES cells 
had no effect on the number of cells showing Saf-A foci compared to controls. 
This suggests that DNA methylation is not critical for memory formation 
(Figure7). 
 Inhibition of sirtuins using Sirtinol, which is a specific HDAC class III 
inhibitor, shows a severe reduction in the number of cells containing Saf-A 
recruitment and very little effect on Xist localization. Xist clusters were similar in 
appearance compared to the controls (Figure 7, 8). These results strongly 
suggest HDAC class III to be involved in the establishment of chromosomal 
memory. 
 For further verification, we analysed the effect of HDAC inhibition on 
endogenously expressed Ash2 protein. For this, ES ∆sxSafA:hrGFP were 
differentiated for seven days in the presence of retinoic acid. 100mM Sirtinol and 
2µM MS275 were added from day 1 to day 5, treating the cells in parallel 
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cultures. At day 7 of differentiation Ash2 and Saf-A recruitment as well as Xist 
localization were analyzed. Controls were cultivated in the absence of inhibitors. 
Xist was induced throughout differentiation in the positive control and after the 
timepoint for memory formation in the negative control (Figure 6). 
As expected, positive as well as negative controls showed Xist localization in the 
vast majority of cells (Figure 9A). Since Xist was not induced during memory 
formation in the negative control, the recruitments of Saf-A as well as Ash2 
protein, which are both dependent on memory, is severely reduced compared to 
the positive control (Figure 9A and 9B). 
MS275 treated cells show a severe reduction of cells containing Saf-A foci, but 
Ash2 recruitment was unaffected. Again, disperse Xist clusters were observed, 
which lead to the assumption that these HDAC inhibitors had led to delocalization 
of Xist. 
 Sirtinol treatment caused a clear reduction of cells containing Ash2 as well 
as Saf-A foci whereas Xist localization was unaffected.  
Since the recruitment of Saf-A as well as Ash2 protein, which are both dependent 
on memory, strongly decreases upon inhibition of sirtuins, we speculate that 
histone H4 Lysine 16 hypoacetylation is a critical component of memory. 
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Figure 7: Reduction of Saf-A recruitment upon early HDAC inhibition in ES ∆sxSafA:hrGFP 
Doxycycline and inhibitors were added at time points during differentiation listed in Figure 2. The 
percentage of cells showing Saf-A ( A) and Xist (B) recruitment is plotted (n=100).  
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Figure 9: Recruitment of Ash2 and SafA upon inhibition of HDAC class II and III 
Doxycycline and inhibitors were added at time points during differentiation listed in Figure 2. The 
percentage of cells showing Ash2 (A), Saf-A (B ) and Xist (C) recruitment is plotted (n=100).  
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Investigation of sirtuin localization 
 
Consistent with the idea that sirtuins act in memory establishment treatment with 
Sirtinol, a specific HDAC class III inhibitor, early during differentiation interferes 
with Saf-A and Ash2 recruitment to the Xi.  
 Mammals possess seven sirtuins (SIRT1-7) that occupy different 
subcellular compartments such as the nucleus (SIRT1, -2, -6, -7), cytoplasm 
(SIRT1 and SIRT2) and the mitochondria (SIRT3, -4 and -5). 
 To verify the importance of sirtuins in the process of X chromosome 
inactivation, we investigated the localization of sirtuins. 
Therefore we performed immunofluorescence staining testing six different 
commercial SIRT1 and two different SIRT2 antibodies on 293-SafA-GFP as well 
as X3-SafA-GFP cells. These cell lines contain three X chromosomes; two of 
them, marked by the recruitment of SafA-GFP protein, are inactive.  
Immunofluorescence staining for SIRT2 showed cytoplasmic localization in both 
X3-SafA-GFP as well as 293-SafA-GFP cells (Figure 7A and 7C). Sirt1 was 
located in the nucleus, but did not show co localization with the SafA-GFP signal 
(Figure 7B).  
 We did not observe co-localization of sirtuins with the inactive X 
chromosome. Therefore, recruitment of Sirtuins to the Xi remains to be shown.  
Nevertheless, our data do not rule out that such recruitment takes place. There 
are technical limitations due to antibody quality that could have prevented us 
from detecting sirtuis at the Xi. Alternatively, sirtuins could be recruited transiently 
to the Xi at a specific interval in differentiation or at a low amount such that 
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detection could be difficult.  It cannot be ruled out that other Sirtuins than Sirt1 
and Sirt2, for which we had antisera available, are involved. Further studies will 
be required to fully address this issue.  
 
 
Figure 10:  
Localization of sirtuins 
SIRT1 and SIRT2 
immunofluorescence 
staining was performed 
using 293-SafA-GFP and 
X3-Saf-A-GFP cells, which 
display two SafA-GFP 
marked inactive X 
chromosomes.  
SIRT2 staining showed 
cytoplasmic localization. 
SIRT2 staining using gene 
tex antibody is illustrated in 
Figure 10A and SIRT2 
antibody from Santa Cruz 
in Figure 10C. SIRT1 
(abcam) showed nuclear 
localization but no co 
localization with Saf-A was 
observed (B). 
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Discussion 
 
The chromosomal memory is a chromatin feature on the X chromosome, which is 
established by Xist at a specific timepoint in early ES cell differentiation. The 
molecular basis of this chromosomal change is presently unknown. 
 Deacetylation of histone H4 represents a chromatin feature that correlated 
with memory and could be a component of its mechanism. Thus, we investigated 
histone H4 deacetylation as a critical component of the chromosomal memory. 
We predicted that acetylated histone H4 would interfere with the recruitment of 
memory. Hence, we tested this prediction by blocking histone deacetylases. 
Among different HDAC inhibitors we identified Sirtinol as a specific class III 
inhibitor that potentially can block memory formation. We show that Saf-A and 
Ash2 recruitment by Xist are impaired when ES cells are differentiated in the 
presence of Sirtinol. Xist localization is not affected under these conditions 
suggesting a defect in chromatin features required for memory. It remains to be 
shown how inhibition of class III HDACs interferes with memory formation and if 
this is a direct effect. In the simplest case it can be envisioned that Sirtuins are 
recruited by Xist to the Xi, where they catalyze deacetylation H4. We have tested 
this hypothesis by immunofluorescence analysis using antisera specific for SirT1 
and SirT2. In these studies we did not observe co-localization of SirT1 and SirT2 
with the inactive X chromosome. Thus, these results do not support our 
hypothesis that Sirtuins are recruited by Xist. However, there are several 
limitations to this interpretation. In principle, the commercial antisera that were 
accessible to us could potentially not be suitable to detect Sirtuins at the Xi. 
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Albeit, this is unlikely as we have used several independent sera, detection could 
be difficult if Sirtuins were transiently recruited or in a low amount. We cannot 
rule out the possibility that members of the SirT family other than SirT1/2 are 
recruited specifically to the Xi. Thus, our failure to detect Sirtuin recruitment by 
Xist does not rule out a direct involvement of class III HDACs in memory 
formation. 
 Future work is needed to elucidate the mechanism of Sirtuin action in X 
inactivation. It will be important to genetically follow up the role of individual SirT 
family HDACs in X inactivation. Approaches using gene targeting or RNAi in ES 
cells will be useful to this end. Furthermore, it has to be clarified what effect 
deacetylation of H4 lysine 16 has on memory imposition. The deacetylation 
reaction produces an unusual metabolite O-acetyl-ADP ribose that has been 
shown in yeast to trigger a change in chromatin structure. It will be interesting to 
see if a similar mechanism is also operative at memory formation during X 
inactivation. Studies into the establishment of heritable epigenetic states in 
mammals are important for questions such as cell identity and gene expression 
control. Thus, unraveling the pathway leading to memory formation in X 
inactivation has important implications for stem cell differentiation and disease. 
Recently, more and more components of the maintenance machinery for the Xi 
are identified such as SmcHD1 (Blewitt et al., 2008). Thus, future research 
promises interesting insights into the underlying molecular mechanism. 
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Project 2: A biochemical approach for the identification 
of factors involved in the initiation of mammalian X 
chromosome inactivation 
 
 
 Introduction 
 
The development of an inducible Xist expression system in male ES cells made it 
possible to experimentally control the initiation of chromosome-wide silencing in 
ES cell differentiation. Investigations using this system showed that chromosomal 
silencing is a two step process. During the initiation phase of X inactivation, Xist 
causes efficient, but reversible gene silencing (Wutz and Jaenisch 2000). Yet, 
after 72 hrs of differentiation Xist is no longer required for maintenance of the 
inactive state (Csankovszki et al., 1999). Taken together these studies strongly 
suggest that early reversible silencing initiates XCI. Upon differentiation a 
transition to a chromatin state occurs that establishes irreversible gene silencing 
and maintenance of XCI (Wutz and Jaenisch 2000).  
 In somatic cells, gene repression on the Xi is maintained by several 
epigenetic mechanisms. Factors that have been implicated in the maintenance of 
X inactivation include DNA methylation, late chromosomal replication and histone 
H4 hypoacetylation (Csankovszki et al., 2001; Csankovszki et al., 1999; Keohane 
et al., 1996; Sado et al., 2000). 
43 
 
 The earliest event in X inactivation is an exclusion of the transcription 
machinery from the Xi chromosome territory. RNA polymerase II, splicing factors 
and nascent transcripts are absent from the Xist covered chromosome. However, 
the formation of this Xist covered chromosome territory is not sufficient for gene 
repression. Initiation of silencing depends on the 5´-end of Xist RNA and a 
specific cellular context that is presented by cells of the early embryo (Savarese 
et al., 2006; Wutz et al., 2002). Thus far, factors that cooperate with Xist the 
initiation of chromosome-wide silencing have not been identified. 
  In order to identify candidates for factors involved in the initiation of X 
chromosome inactivation, we aimed at the biochemical isolation of the Xist 
containing complexes from ES cells. For this we devised a protocol to isolate the 
nuclear fraction in which Xist is contained and to detect proteins that become 
enriched upon X inactivation. 
 
 
Experimental strategy 
 
To identify candidate proteins that interact with Xist RNA we aimed to compare 
ES cells with an inactive X chromosome to ES cells with an active X 
chromosome. In our experimental design, we used ES cells which have an 
inducible Xist allele on the X chromosome such that inactivation can be triggered 
by addition of doxycycline to the growth medium (Figure 11). 
 Xist RNA has been observed to remain in the nuclear matrix. This suggests 
that a specific nuclear fraction that is enriched for Xist RNA can be isolated. 
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Therefore, we focused our biochemical purification on the nuclear fraction that 
contains Xist. Importantly, this would remove chromatin from nuclei by DNA 
digestion and protein salt extraction effectively eliminating bulk histones and 
other abundant nuclear factors. We reasoned that we subsequent might be able 
to specifically extract candidate proteins from this fraction by digestion Xist RNA. 
Proteins becoming soluble after RNA digestion can be analysed by mass 
spectrometry.  
 Analysis of complex protein mixtures has become possible due to recent 
developments in mass spectrometric methodology (REFs: Mathias Mann review; 
Mann and Schoeler Hans 5000 proteins in ES cells by SILAC). Comparison of 
protein fractions between two samples requires a quantitative approach to 
proteomics. This can be achieved in a first approximation by integration of peak 
areas of mass spectra. Precise quantification requires methods for labelling the 
peptides with different masses. This can be achieved by incorporation of isotopic 
aminoacids. One sample is labelled with light amino acids and compared to cells 
labelled with amino acids containing heavy nitrogen and carbon isotopes (15N 
and 13C).  
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Figure 12: Experimental design to compare protein levels of ES (Xi) to ES (Xa) 
ES cells with an inactive X are labelled with light amino acids and ES cells with an active X with 
heavy amino acids. Subsequently, chromatin is removed from nuclei by DNA digestion and protein 
salt extraction. The remaining Xist containing fraction is isolated. Proteins becoming soluble after 
RNA digestion are analysed by mass spectrometry. 
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 Results 
 
Xist RNA remains in fixed nuclear matrix fraction of ES cells 
 
Earlier studies in female human epithelial cells have shown that XIST RNA 
remains in the nuclear matrix fraction. After DNA digestion and chromatin 
extraction XIST was detected by RNA fluorescence hybridization (Clemson et al., 
1996). We adopted this strategy for optimization of extraction of the Xist 
containing nuclear fraction from ES cells using glass slides. 
 To investigate the efficiency of different DNA digesting enzymes, 
∆sxSafA:hrGFP ES cells were grown on multiwell glass slides (Roboz slides), 
washed in cytoskeletal buffer and salt extracted. DNA was either digested with 
DNAse I or PstI and HaeIII. Preparations treated with PstI and HaeIII showed 
intense DNA staining suggesting inefficient removal of chromatin. In contrast, 
cells treated with 10U/100µl DNAse I showed minimal residual DNA staining 
(data not shown). Thus, DNAse allowed effective removal of chromatin and was 
suitable for our purification scheme. 
 To investigate whether Xist RNA is retained after removal of bulk chromatin, 
biochemical fractionation procedures were examined that have been previously 
used to isolate insoluble nuclear fractions termed matrix and that remove 90-95 
% of cellular DNA, proteins and phospholipids (Berezney and Coffey, 1974). 
 
For this, ∆sxSafA:hrGFP ES cells were used that contain an inducible Xist allele on 
the X chromosome, which lacks the 5´-end and does not trigger gene silencing. 
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In addition these cells contain a transgene for expression of a Saf-A:hrGFP 
fusion protein. Xist was induced for 24 hours by addition of doxycycline to the 
culture. Cell fractionation was performed in the following steps. 
 After cells were washed in PBS, preextraction with cytoskeletal buffer was 
performed. Chromatin was removed using ammonium sulphate extraction and 
DNA digestion using 10U/100µl DNAse I. A second extraction with ammonium 
sulphate was performed. The presence of Xist RNA was analysed using 
fluorescence in situ hybridization (FISH) after each fractionation step. Samples 
before fractionation as well as samples which were preextracted with cytoskeletal 
buffer, showed distinct Xist clusters. However, Xist did not remain in the insoluble 
fraction after treating the cells with ammonium sulphate. Minimal residual DNA 
staining was observed after DNA digestion and salt extraction (Figure 13).  
 These data indicate that Xist RNA is not retained after stringent extraction 
of the nuclear matrix suggesting that Xist binding was not stable in ES cells. Xist 
stability might have been compromised due to lack of the repeat A of Xist in 
∆sxSafA:hrGFP ES cells or short Xist induction time.  
  To circumvent these stability problems, the experiment was repeated in 
mouse ES cells which carry an inducible Xist cDNA transgene, which includes 
the repeat A, inserted into chromosome 11 (Wutz and Jaenisch, 2000). Induction 
of transgenic Xist recapitulates all known chromatin changes of X inactivation 
and causes silencing of the autosome. 
 Xist was induced for 3 days by doxycycline. Subsequently, cell extraction 
was performed as described above. Additionally, the effect of higher amounts of 
DNAse I for more efficient DNA digestion was investigated. We compared 
treatment with 10U/100µl to treatment with 100U/100µl. Residual DNA staining of 
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both samples did not show any difference; indicating that 10U of DNAse is 
already a sufficient for complete digestion of chromatin. Analysis of the samples 
by FISH showed that Xist RNA was not retained after extraction of the cells with 
ammonium sulphate (Figure 14).  
 Hence, both ∆sxSafA:hrGFP  ES as well as 36.11 ES cells showed Xist loss 
after extracting the cells with ammonium sulphate. We conclude from these data 
that Xist does not retain in the nuclear matrix of undifferentiated ES cells.  
In order to stabilize Xist in the nuclear matrix fraction of ES cells we aim to 
enhance Xist binding to the matrix. Sodium tetrathionate is known to stabilize 
selectively nuclear matrix proteins by oxidizing sulfhydryl groups to disulfides. We 
anticipated that fixing ES cells with sodium tetrathionate leads to better 
preservation of nuclear matrix and thus might retain Xist RNA. 
 36.11 ES cells were cultivated in the presence of doxycycline for 3 days. 
Cells were preextracted in the presence of 2mM sodium tetrathionate and 
nuclear matrix extraction was performed as described above. Xist fluorescence in 
situ hybridization showed Xist RNA to remain after extracting the cells with 
ammonium sulphate as well as after whole fractionation procedure (Figure 15). 
Thus, mild fixation with tetrathionate allowed me to devise a procedure that leads 
to the retention of Xist RNA in a partially purified nuclear matrix fraction of 
undifferentiated ES cells. 
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Figure 13: Xist fluorescence in situ hybridization of fractionated ES ∆sxSafA:hrGFP cells 
ES cells were preextracted with cytoskeletal buffer (B) and salt extracted with ammonium sulphate 
C). After DNA digestion (D), cells were again salt extracted (E). Samples before fractionation are 
shown (A). DNA was stained with DAPI. SAF-A is a nuclear matrix component of the Xi in 
differentiated cells but not of ES cells. 
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Figure 14: Xist fluorescence in 
situ hybridization of chromatin 
extracted 36.11 ES cells 
ES cells were preextracted with 
cytoskeletal buffer (B) and salt 
extracted with ammonium sulphate 
(C). After DNA digestion 
(10U/100µl) (D), cells were again 
salt extracted (F and G). DNA was 
digested using 10U/100µl (F) or 
100U/100µl DNAse I (G). Samples 
before nuclear extraction are 
shown (A). DNA was stained with 
DAPI. 
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Figure 15: Xist fluorescence in situ hybridization of 36.11 ES cells extracted cells using 
sodium tetrathionate 
ES cells were preextracted with cytobuffer in the presence of 2mM sodium tetrathionate and salt 
extracted with ammonium sulphate (B). After DNA digestion (10U/100µl), cells were again salt 
extracted (C). Samples before fractionation procedure is shown (A). DNA was stained with DAPI.  
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Optimization of biochemical ES cell fractionation 
 
For large scale preparative isolation of nuclear fractions containing Xist the 
optimized procedure from glass slides was adopted for a biochemical approach. 
For this nuclei were isolated from ES cells and fractionation steps to obtain a 
nuclear fraction suitable for detection of factors involved in the initiation phase of 
X chromosome inactivation were optimized. 36.11 ES cells were cultivated in the 
presence of doxycycline for 2 days to induce Xist expression. After harvesting the 
cells by trypsinization, nuclei were isolated to remove the cytoplasm. 
Subsequently, chromatin was removed by ammonium sulphate extraction and 
DNA digestion using 10U/100µl DNAse I. A second extraction with ammonium 
sulphate was performed to remove the digested chromatin. From the residual 
fraction proteins were then solubilised by RNAse treatment and analysed.  
 In order to obtain relatively pure and defined fractions we optimized several 
steps of this protocol. We attempted to isolate nuclei from ES cells using a 
Dounce glass homogenizer with loose fitting pestle. Following homogenization, 
nuclei were separated through a sucrose cushion. This protocol gave a viscous 
and ill defined pellet indicating nuclear lysis. Since nuclei were not intact and 
leaking DNA led to extreme viscosity subsequent treatment with ammonium 
sulphate and DNAse did not resolve the pellet. Therefore, chromatin could not be 
extracted from this preparation and an alternative protocol had to be envisioned. 
The destruction of the nuclei might have resulted from using a hypotonic sucrose 
gradient or from too strong shearing during homogenization.      
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Hence, we aimed to isolate intact nuclei, using a ficoll gradient, instead of 
sucrose gradient, which contains NP-40 and Triton. This method allows 
performing the destruction of the cell membrane and harvesting of nuclei by 
density gradient in one step.  
 ES cells were overlaid onto a cushion containing ficoll, NP-40 and Triton. 
Subsequent centrifugation separated nuclei from cytoplasm. We obtained intact 
nuclei suitable for our fractionation procedure.  
 Yet, we observed that DNA was not digestible after ammonium sulphate 
salt extraction. Therefore, digestion of DNA was performed directly after nuclei 
isolation. This allowed proper DNA digestion and subsequent salt extraction. 
Subsequently, we treated the remaining nuclear fraction with RNAse to obtain 
solubilise candidate proteins by digesting Xist RNA. 
 In order to characterise the biochemical fractionation, we performed 
western blot analysis of different fractions. The nuclear scaffold factor Saf-A has 
been detected in the nuclear matrix fraction after chromatin removal (Helbig and 
Fackelmayer, 2003). Thus, Saf-A serves as a positive control for the insoluble 
nuclear matrix fraction. In addition, Saf-A has been reported to be enriched on 
the inactive X chromosome (Helbig and Fackelmayer, 2003). This localization 
depends on its RNA binding RGG domain, which suggests a possible direct 
interaction between Saf-A and Xist. Therefore, we reasoned that Saf-A might 
also localize in the soluble fraction after RNA digestion of the nuclear matrix in 
ES cells in an Xist dependent manner.  Lamins are components of the nuclear 
lamina, which is a structure near the inner nuclear membrane and the peripheral 
chromatin. The internal lamins that connect to nuclear pore complexes are major 
structural elements of the internal nuclear matrix. Therefore, lamins are expected 
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to be in the insoluble nuclear matrix fraction. The highly abundant histones are 
the main protein components of chromatin, which we aimed to remove in the 
fractionation procedure by DNAse treatment and salt extraction.  
 We extracted nuclear matrix of ES 36.11 cells and performed western blot 
analysis of different cell fractions (Figure16). As expected, Saf-A was found to a 
large extent in the insoluble nuclear matrix fraction and to a minor extent in the 
soluble fraction after RNAse treatment. In contrast, lamines were detected only in 
the insoluble nuclear matrix fraction. Neither Saf-A nor lamin was observed in the 
cytoplasmic fraction, suggesting an isolation of intact nuclei. In the soluble 
fraction only a low amount of histones was detected. RNAse A, which was added 
in a large amount to extract the nuclear matrix fraction, did not give any 
background signal on Western blots revealed either with the Saf-A or lamin A 
antibodies.  
 These data indicated that, following this cell fractionation procedure, we 
obtained a soluble nuclear matrix fraction suitable for proteomic analysis.  
The soluble fraction obtained from nuclear matrix was analysed by mass 
spectrometry by Karl Mechtler (Table 1). The data indicated that histone proteins 
are only a minor constitutent of the sample and did not prevent the identification 
of other less abundant nuclear proteins. Thus, our strategy of chromatin removal 
before candidate protein extraction was successful. We aimed at an initial 
comparison of samples prepared from cells treated with doxycycline for induction 
of Xist expression and untreated controls. For this we used the number of 
peptides identified for each protein as an indication of relative protein abundance 
in the samples. This is a measure which presents various caveats but can be 
applied for an initial characterization. A more robust approach is to measure the 
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peak areas of characteristic mass peaks in the spectra and set these integrated 
peak areas in relation. Using both methods several proteins were identified as a 
candidate factor that could be potentially become enriched in the nuclear matrix 
fraction after Xist expression. However, the observed enrichment was low, on 
average 3.5 fold and required an independent confirmation. Among the potential 
candidates we observed Trim28, which was of interest because it had been 
previously been implicated in retroviral silencing and host defense in ES cells 
(Wolf and Goff, 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Analysis of Saf-A, lamin A  and histone H3 in ES 36.11 cell fractions 
ES 36.11 cells were grown for 48h followed by nuclear matrix extraction. Saf-A is shown to be 
abundant in the soluble as well as in the insoluble fraction, whereas lamin A was detected only in 
the insoluble fraction. Saf-A and Lamin A were not observed in the cytoplamsic fraction as well as 
in the RNAse control. Histone were only very little abundant in the soluble fraction. 
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The preliminary analysis of nuclear matrix extraction using glass slides showed 
Xist to remain in the matrix fraction of ES cells only after fixation. Therefore we 
intended to isolate the Xist containing fraction of fixed nuclei, using a biochemical 
fractionation procedure.  
For this 36.11 ES cells were cultivated in the presence of doxycycline for 2 days 
and nuclei were isolated as described above. In order to fix nuclei, they were 
washed with PBS in the presence of 2mM tetrathionate sulphate for 10 minutes. 
Following extraction with ammonium sulphate yielded sticky nuclear pellet. We 
obtained nuclei, which are more stable, when we washed them with ficoll 
containing buffer in the presence of tetrathionate. In addition we attempted to 
digest DNA directly after fixation followed by salt extraction. In this way we 
obtained a nuclear matrix fraction that could be extracted by RNA digestion. In 
order to verify our fractionation procedure, we performed western blot analysis to 
detect Saf-A and Lamin B, which are components of the nuclear matrix (Figure 
17). As expected, we identified high levels of Saf-A as well as lamin-B in the 
insoluble fraction of the nuclear matrix. In comparison to the fractions of unfixed 
nuclei, we observed that Saf-A was not solubilised after RNA digestion. This 
might be due to better preservation of the nuclear matrix. We observed a small 
amount of Saf-A in the supernatant after extraction with ammonium sulphate, 
meaning that a small amount of Saf-A became soluble while chromatin was 
soluble. Lamin B was present mainly in isolated nuclei, the supernatant after salt 
extraction and the insoluble nuclear matrix pellet. In contrast very little lamin B 
was observed in the soluble fraction after RNAse treatment.  The soluble fraction 
after RNAse treatment of the nuclear matrix was analysed by mass spectrometry 
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by Karl Mechler (Table 2). Several proteins were detected in these fractions but 
the number of identified proteins appeared lower than of fraction from cells that 
were not fixed with Tetrathionate. Some proteins showed enrichment after Xist 
induction but these seemed to belong to the class of general RNA binding 
proteins or nucleolar components. Thus, the proteins were of little interest for 
followup studies as they did not provide a link to chromatin or gene regulation. 
 
        
 
 
Figure 17: Detection of Saf-A and lamin  in nuclear fractions of fixed nuclei 
ES 36.11 cells were grown for 48h followed by nuclear matrix extraction. Saf-A is shown to be 
abundant in the insoluble fraction compared to the soluble fraction. Lamin A was detected in the 
insoluble fraction and showed very little lamin B was observed in the soluble fraction. Lamin A 
and Saf-A was detected in the nuclei. 
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Analysis of Trim 28 upon Xist expression in ES cells 
 
Preliminary mass spectrometric analysis of unfixed soluble fractions indicated 
Trim28 as a candidate factor that showed potential enrichment in the nuclear 
matrix fraction upon Xist induction. Trim 28 was of interest, because it is a known 
transcriptional silencer and was previously shown to repress transcription of 
proviral DNAs from moloney murine leukemia virus in embryonic carcinoma and 
ES cells (Wolf and Goff, 2007). 
 To confirm the abundance of Trim28 in the soluble fractions, we aimed to 
identify Trim28 by western blot analysis. Therefore we used an affinity purified 
antibody from everest biotech, which has been tested in human and mouse and 
recognizes a band at approximately 100 – 120kDa. Different dilutions of the 
antibody were tested on total ES cell extract. For this 36.11 ES cells were 
cultivated in the presence of doxycycline for 48 hours. For comparison, 36.11 ES 
cells were cultivated without Xist induction. Cells were harvested; total cell 
extract was prepared and loaded on a polyacrylamide gel. Western blot analysis 
showed many unspecific bands indicating antibody background staining. No 
band at the correct size of 100 – 120kDa was observed (data not shown). 
Therefore, we tried 2 further antibodies, which are commercially available: 
Trim28 specific antibodies from bethyl laboratories and from abcam are both 
affinity purified and tested in human. They identify a band at approximately 110 
kDa. Different dilutions of both antibodies were tested on total ES cell extract. A 
strong band at the size of 120 kDa was observed using both antibodies at a high 
dilution (bethyl: 1:20000 and abcam: 1:2000) and thus can be regarded as 
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Table 1: Mass spectrometric analysis of nuclear matrix extracts
Protein name and accession number is shown for each protein. The peptide areas and their ratios  are shown of canditates of intere
Protein name Acc. Nr. minus dox plus dox Ratio
Strbp :: Spermatid perinuclear RNA binding protein - Mus musculus (Mouse); Mice 
homozygous for a gene trap insertion exhibit premature death, a reduced body size 
and an abnormal clutching reflex. Minor brain abnormalities and spermatogenesis 
defects were also noted. A2BH81|A
49882607 193843072 1 : 3.89
Ilf3 / NF90 :: Nuclear factor 90 - Mus musculus (Mouse) Q45VK5| 146654680 465693087 1 : 3.18
Ddx3x X-linked embryonic RNA helicase :: 2 cells egg cDNA, RIKEN full-length 
enriched library, clone:B020006B14 product:DEAD/H - Mus musculus (Mouse) Q3TQX5 16552490 169999338 1 : 10.3
Myef-2 :: Myelin basic protein expression factor 2, repressor - Mus musculus (Mouse) A2ATP5|A 8915096 29431584 1 : 3.3
CRL-1722 L5178Y-R cDNA, RIKEN full-length enriched library, clone:I730096G03 
product:heterogeneous nuclear ribonucleoprotein M, full insert sequence - Mus 
musculus (Mouse) Q3THB3|
17 days embryo heart cDNA, RIKEN full-length enriched library, clone:I920087O13 
product:vimentin, full insert sequence - Mus musculus (Mouse) Q3TFD9|
DEAD - Mus musculus (Mouse) A1L333|A
Lung RCB-0558 LLC cDNA, RIKEN full-length enriched library, clone:G730022P12 
product:heterogeneous nuclear ribonucleoprotein L, full insert sequence - Mus 
musculus (Mouse) Q3UMT7
Dhx15 :: 16 days embryo kidney cDNA, RIKEN full-length enriched library, 
clone:I920087J23 product:DEAH - Mus musculus (Mouse) Dhx15 Q3TFE5| 5497081 18413779 1 : 3.35
Osteoclast-like cell cDNA, RIKEN full-length enriched library, clone:I420039N16 
product:heterogeneous nuclear ribonucleoprotein U, full insert sequence - Mus 
musculus (Mouse) Q3TVV6|
Mov10 :: 17 days pregnant adult female amnion cDNA, RIKEN full-length enriched 
library, clone:I920090G16 product:Moloney leukemia virus 10, full insert sequence - 
Mus musculus (Mouse) Q3TFC0|
50601365 99000950 1 : 1.96
13 days embryo liver cDNA, RIKEN full-length enriched library, clone:I920036O16 
product:proliferation-associated 2G4, full insert sequence - Mus musculus (Mouse) Q3TGU7
13128466 54831764 1 : 4.18
2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, 
clone:E430022F21 product:annexin A2, full insert sequence - Mus musculus (Mouse) Q542G9|
Bone marrow macrophage cDNA, RIKEN full-length enriched library, 
clone:I830165N20 product:ribosomal protein S3a, full insert sequence - Mus musculus
(Mouse) Q3U5P8|
Insulin-like growth factor 2 mRNA binding protein 2 - Mus musculus (Mouse) A6X8Z3|A nd 41754682 nd : 1
12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, 
clone:D130062P10 product:ELAV - Mus musculus (Mouse) Q3UR02| 4089494 13659408 1 : 3.34
Blastocyst blastocyst cDNA, RIKEN full-length enriched library, clone:I1C0040A22 
product:ribosomal protein S17, full insert sequence - Mus musculus (Mouse) Q3TK12|
nd 54245047 nd : 1
Heterogeneous nuclear ribonucleoprotein A3 - Mus musculus (Mouse) A2AL12|A
matrin 3 :: 10 days neonate skin cDNA, RIKEN full-length enriched library, 
clone:4732457K09 product:matrin 3, full insert sequence - Mus musculus (Mouse) Q3TTX0| 80669494 323605916 1 : 4.01
S1 protein C2 - Mus musculus (Mouse) Q20BD0|
Non-muscle alpha-actinin 4 - Mus musculus (Mouse) Q1A602|Q
Ribosomal protein S3 - Mus musculus (Mouse) Q5YLW3
Rps9 protein - Mus musculus (Mouse) Q96EC0|
2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, 
clone:E430001E01 product:ribosomal protein L10A, full insert sequence - Mus 
musculus (Mouse) Q3U561|
U1 small nuclear ribonucleoprotein polypeptide A - Mus musculus (Mouse) A2RS68|A
Bone marrow macrophage cDNA, RIKEN full-length enriched library, 
clone:I830128K02 product:RNA binding motif protein 14, full insert sequence - Mus 
musculus (Mouse) Q3U6A2|
MCM3 :: 17 days embryo heart cDNA, RIKEN full-length enriched library, 
clone:I920096F09 product:DNA replication licensing factor MCM3 - Mus musculus 
(Mouse) Q3UI57|Q
nd 10832015 nd : 1
Rbm39 protein - Mus musculus (Mouse) Q0VGU9
Rpl30 protein - Mus musculus (Mouse) Q497D7|
Ribosomal protein S25 - Mus musculus (Mouse) Q58EA6|
Rpl17 protein - Mus musculus (Mouse) Q505B1|Q
Ras-GTPase-activating protein binding protein 2 - Mus musculus (Mouse) :: 2 days 
neonate thymus thymic cells cDNA, RIKEN full-length enriched library, 
clone:E430003G24 product:Ras-GTPase-activating protein binding protein 2 - Mus 
musculus (Mouse) Q3U541|
nd 17408498 nd : 1
importin alpha :: Karyopherin - Mus musculus (Mouse) Q52L97|Q nd 14968214 nd : 1
12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, 
clone:D130013C23 product:DEAH - Mus musculus (Mouse) Q3UR42|
Actin, gamma, cytoplasmic 1 - Mus musculus (Mouse) Q4KL81|Q
Areas (sum of peptid-area)
Bone marrow macrophage cDNA, RIKEN full-length enriched library, 
clone:I830015L07 product:nuclease sensitive element binding protein 1, full insert 
sequence - Mus musculus (Mouse) Q3UBT1|
ELAV-LIKE PROTEIN 1 :: 12 days embryo embryonic body between diaphragm 
region and neck cDNA, RIKEN full-length enriched library, clone:9430002B02 
product:ELAV-LIKE PROTEIN 1 - Mus musculus (Mouse) Q8BM84
170127674 469842908 1 : 2.76
Poly A binding protein, cytoplasmic 4 - Mus musculus (Mouse) A3KFU5|
TRIM28 :: Tripartite motif protein 28 - Mus musculus (Mouse) Q5EBP9| 19472290 64635464 1 : 3.32
Bone marrow macrophage cDNA, RIKEN full-length enriched library, 
clone:I830035O17 product:ribosomal protein L3, full insert sequence - Mus 
musculus (Mouse) Q3U9L3|
14353175 40426566 1 : 2.82
2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, 
clone:E430010B17 product:ribosomal protein L4, cytosolic homolog - Mus musculus 
(Mouse) Q564E8|Q
Adult male testis cDNA, RIKEN full-length enriched library, clone:1700012H05 
product:TESTES SPECIFIC HETEROGENOUS NUCLEAR RIBONUCLEOPROTEIN 
G-T homolog - Mus musculus (Mouse) Q9DAE2
3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630098I22 
product:TAR DNA binding protein, full insert sequence - Mus musculus (Mouse) Q3U591|
Rpl23a protein - Mus musculus (Mouse) Q4V9X9|
Osteoclast-like cell cDNA, RIKEN full-length enriched library, clone:I420032B10 
product:ribosomal protein S18, full insert sequence - Mus musculus (Mouse) Q3TW65
Ribosomal protein S8 - Mus musculus (Mouse) Q497E9|Q
CRL-1722 L5178Y-R cDNA, RIKEN full-length enriched library, clone:I730084D22 
product:Hypothetical RNA binding protein RDA288 homolog - Mus musculus (Mouse) Q3UJK2|
60S acidic ribosomal protein P0 - Mus musculus (Mouse) Q5FWB6
Activated spleen cDNA, RIKEN full-length enriched library, clone:F830208A11 
product:DEAD - Mus musculus (Mouse) Q3T9L0|Q
Ribosomal protein L7a - Mus musculus (Mouse) Q58ET1|
Bone marrow macrophage cDNA, RIKEN full-length enriched library, 
clone:I830082P18 product:ribosomal protein L15, full insert sequence - Mus musculus 
(Mouse) Q3U7D2|
15 days pregnant adult female placenta cDNA, RIKEN full-length enriched 
library, clone:I530023K22 product:tropomyosin 3, gamma, full insert sequence - 
Mus musculus (Mouse) Q3TJ53|Q
60S ribosomal protein L6 - Mus musculus (Mouse) Q3UCH0
Small nuclear ribonucleoprotein D3 - Mus musculus (Mouse) Q91VM2
Hnrpf protein - Mus musculus (Mouse) hnRNP F Q8R582|
Heterogeneous nuclear ribonucleoprotein H2 - Mus musculus (Mouse) A2BDV8|
Sf3b1 protein - Mus musculus (Mouse) A0JLN0|A 783400 1064688 1 : 1.36
CRL-1722 L5178Y-R cDNA, RIKEN full-length enriched library, clone:I730098H14 
product:splicing factor, arginine/serine-rich 7, full insert sequence - Mus musculus 
(Mouse) Q3THA6|
Splicing factor proline/glutamine rich - Mus musculus (Mouse) A2A7U6|A
Ribosomal protein L14 - Mus musculus (Mouse) Q569Z0|Q
60S ribosomal protein L36 - Mus musculus (Mouse) Q5M9L1|
OTTMUSP00000017203 - Mus musculus (Mouse) A3KGK6|
Zfp326 Zn-finger nucl. Matrix 16 :: days neonate thymus cDNA, RIKEN full-
length enriched library, clone:A130002H22 product:zinc finger protein 326, full 
insert sequence. - Mus musculus (Mouse) Q3TRI9|Q
Sf3b2 :: Bone marrow macrophage cDNA, RIKEN full-length enriched library, 
clone:I830028H02 product:splicing factor 3b, subunit 2, full insert sequence - Mus 
musculus (Mouse) Q3UAI4|Q
nd 24338481 nd : 1
Annexin A11 - Mus musculus (Mouse) Q921F1|Q
Far upstream element - Mus musculus (Mouse) FuBp3 A2AJ72|A nd 22006945 nd : 1
Ribosomal protein L19 - Mus musculus (Mouse) A2A547|A
Rps19 protein - Mus musculus (Mouse) Q5M9P3
Mi2beta = Chd4 -> NuRD :: MKIAA4075 protein - Mus musculus (Mouse) Q5DTP7| nd 13129123 nd : 1
nucleolin :: Blastocyst blastocyst cDNA, RIKEN full-length enriched library, 
clone:I1C0002A07 product:nucleolin, full insert sequence - Mus musculus (Mouse) Q3TL52|Q
1,522E+09 4833901496 1 :3.18
Bone marrow macrophage cDNA, RIKEN full-length enriched library, 
clone:I830045N07 product:heterogeneous nuclear ribonucleoprotein R, full insert 
sequence - Mus musculus (Mouse) Q3U8W9
Ilf2 :: 12 days embryo female mullerian duct includes surrounding region cDNA, 
RIKEN full-length enriched library, clone:6820446H05 product:interleukin enhancer 
binding factor 2, full insert sequence - Mus musculus (Mouse) Q3UXI9|Q
107790080 660508460 1 : 6.13
Heterogeneous nuclear ribonucleoprotein H1 - Mus musculus (Mouse) Q811L7|Q
In vitro fertilized eggs cDNA, RIKEN full-length enriched library, clone:7420408C23 
product:heterogeneous nuclear ribonucleoprotein D, full insert sequence. - Mus 
musculus (Mouse) Q3UXC8
Elongation factor 1-alpha - Mus musculus (Mouse) Q3TII3|Q 11841542 66563102 1 : 5.62
TIB-55 BB88 cDNA, RIKEN full-length enriched library, clone:I730008D20 
product:ribosomal protein L12, full insert sequence - Mus musculus (Mouse) Q3TIQ2|Q
12 days embryo embryonic body between diaphragm region and neck cDNA, RIKEN 
full-length enriched library, clone:9430049D01 product:synaptotagmin binding, 
cytoplasmic RNA interacting protein, full insert seque... - Mus musculus (Mouse) Q3TRV3|
MKIAA0138 protein - Mus musculus (Mouse) Q6A0C0|
Ribosomal protein S21 - Mus musculus (Mouse) A2ABW8
Nuclear pore complex-associated intranuclear coiled-coil protein TPR - Mus musculus 
(Mouse) Q7M739|
CRL-1722 L5178Y-R cDNA, RIKEN full-length enriched library, clone:I730073G06 
product:60S ribosomal protein L18a, full insert sequence - Mus musculus (Mouse) Q3THJ0|
1 cell embryo 1 cell cDNA, RIKEN full-length enriched library, clone:I0C0016F01 
product:TAF15 RNA polymerase II, TATA box binding protein - Mus musculus 
(Mouse) Q3TLE4|
CRL-1722 L5178Y-R cDNA, RIKEN full-length enriched library, clone:I730022O16 
product:ribosomal protein S15, full insert sequence - Mus musculus (Mouse) Q3UK70|
Alpha actinin 1a - Mus musculus (Mouse) A1BN54|A
17 days embryo kidney cDNA, RIKEN full-length enriched library, clone:I920078L09 
product:FUS interacting protein - Mus musculus (Mouse) Q3TFP0|
Mcm5 :: Minichromosome maintenance deficient 5, cell division cycle 46 - Mus 
musculus (Mouse) Q52KC3| 1103857 6564275 1 : 5.95
12 days embryo male wolffian duct includes surrounding region cDNA, RIKEN full-
length enriched library, clone:6720473C09 product:small nuclear ribonucleoprotein 
polypeptide A', full insert sequence - Mus musculus (Mouse) Q8BSH5
NOD-derived CD11c +ve dendritic cells cDNA, RIKEN full-length enriched library, 
clone:F630010M18 product:ribosomal protein L13a, full insert sequence - Mus 
musculus (Mouse) Q3TDS9|
Ribosomal protein L28 - Mus musculus (Mouse) Q5M9J8|
Ribosomal protein L38 - Mus musculus (Mouse) Q52KP0|
Ribosomal protein S15a - Mus musculus (Mouse) Q5M9M4
Ribosomal protein L11 - Mus musculus (Mouse) A2BH06|A
Ahnak protein - Mus musculus (Mouse) A0JLR7|A
Puf60 protein - Mus musculus (Mouse) FIR Q0VDY2 nd 12346746 nd : 1
Peptidyl-prolyl cis-trans isomerase - Mus musculus (Mouse) Q3UBU9
Rpl18 protein - Mus musculus (Mouse) Q58EW0
Grwd1 protein - Mus musculus (Mouse) Q5XJZ3|Q
Processing of 1, ribonuclease P/MRP family, - Mus musculus (Mouse) Q8K205|Q
0 day neonate thymus cDNA, RIKEN full-length enriched library, clone:A430101M19 
product:ribosomal protein S5, full insert sequence - Mus musculus (Mouse) Q91V55|Q
10, 11 days embryo whole body cDNA, RIKEN full-length enriched library, 
clone:2810036L13 product:SIMILAR TO SMOOTH homolog - Mus musculus (Mouse) Q9CSH0
Splicing factor 3a, subunit 3 - Mus musculus (Mouse) Q58E59|Q nd 11120634 nd : 1
Ribosomal protein L9 - Mus musculus (Mouse) Q5EBQ6
Sf3a1 :: Osteoclast-like cell cDNA, RIKEN full-length enriched library, 
clone:I420047E18 product:splicing factor 3a, subunit 1, full insert sequence - Mus 
musculus (Mouse) Q3TVM1
nd 6365837 nd : 1
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon 
polypeptide - Mus musculus (Mouse) Q5SS40|
6 days neonate spleen cDNA, RIKEN full-length enriched library, clone:F430009E14 
product:thymopoietin, full insert sequence - Mus musculus (Mouse) Q3TNH0
clone:I830046M23 product:poly A binding protein, cytoplasmic 1, full insert sequence - Q3U8U8|
5 days embryo whole body cDNA, RIKEN full-length enriched library, 
clone:I0C0047C10 product:heterogeneous nuclear ribonucleoprotein K, full insert 
sequence - Mus musculus (Mouse) Q3TL71|Q
17 days pregnant adult female amnion cDNA, RIKEN full-length enriched library, 
clone:I920058I09 product:Sjogren syndrome antigen B, full insert sequence - Mus 
musculus (Mouse) Q3TG93|
B6-derived CD11 +ve dendritic cells cDNA, RIKEN full-length enriched library, 
clone:F730215J21 product:heat shock protein 8, full insert sequence. - Mus musculus 
(Mouse) Q3TB63|
MRT4, mRNA turnover 4, homolog - Mus musculus (Mouse) A2AMU9
CRL-1722 L5178Y-R cDNA, RIKEN full-length enriched library, clone:I730064N19 
product:guanine nucleotide binding protein, beta 2, related sequence 1, full insert 
sequence - Mus musculus (Mouse) Q3THP0|
D19Bwg1357e protein - Mus musculus (Mouse) Q7TMX0
Tcof1 protein - Mus musculus (Mouse) Q05BH6|
CDNA, RIKEN full-length enriched library, clone:I920161F21 product:poly(rC) binding 
protein 2, full insert sequence - Mus musculus (Mouse) Q3TF69|Q
12 days embryo female mullerian duct includes surrounding region cDNA, RIKEN full-
length enriched library, clone:6820407G10 product:ribosomal protein S4, X-linked, full 
insert sequence - Mus musculus (Mouse) Q3UXQ6
B16 F10Y cells cDNA, RIKEN full-length enriched library, clone:G370049E15 
product:GPI-anchored membrane protein 1, full insert sequence. - Mus musculus 
(Mouse) Q3UFZ6|
16 days embryo head cDNA, RIKEN full-length enriched library, clone:C130041B04 
product:annexin A1, full insert sequence - Mus musculus (Mouse) Q3US43|
Blastocyst blastocyst cDNA, RIKEN full-length enriched library, clone:I1C0037A13 
product:hypothetical Zn-finger, C-x8-C-x5-C-x3-H type containing protein, full insert 
sequence - Mus musculus (Mouse) Q3UL31|
Rps16 protein - Mus musculus (Mouse) A4FUS1|
40S ribosomal protein S12 - Mus musculus (Mouse) Q6ZWZ6
60S ribosomal protein L27 - Mus musculus (Mouse) Q5BLJ9|Q
Small nuclear ribonucleoprotein B - Mus musculus (Mouse) A2APD4|
Ribosomal protein L37a - Mus musculus (Mouse) Q4VAF2|
Ribosomal protein L22 - Mus musculus (Mouse) Q4VAG4
ES cells cDNA, RIKEN full-length enriched library, clone:2400004P05 
product:ribosomal protein L27a, full insert sequence - Mus musculus (Mouse) Q9CQ16
Peptidyl-prolyl cis-trans isomerase - Mus musculus (Mouse) Q9DCY1
Bone marrow macrophage cDNA, RIKEN full-length enriched library, 
clone:I830014L05 product:ribosomal protein S11, full insert sequence - Mus musculus 
(Mouse) Q3UC02|
TIB-55 BB88 cDNA, RIKEN full-length enriched library, clone:I730044G20 
product:ribosomal protein S2, full insert sequence - Mus musculus (Mouse) Q3TI78|Q
RNP particle component - Mus musculus (Mouse) O08905|O
MKIAA4115 protein - Mus musculus (Mouse) Q571F9|Q
Anxa6 protein - Mus musculus (Mouse) Q99JX6|Q
CRL-1722 L5178Y-R cDNA, RIKEN full-length enriched library, clone:I730029B08 
product:heterogeneous nuclear ribonucleoprotein A1, full insert sequence - Mus 
musculus (Mouse) Q3TIK8|Q
Bone marrow macrophage cDNA, RIKEN full-length enriched library, 
clone:I830120C02 product:heterogeneous nuclear ribonucleoprotein C, full insert 
sequence - Mus musculus (Mouse) Q3U6P5|
HnRNP-associated with lethal yellow - Mus musculus (Mouse) A2AU62|A
Rbmxrt protein - Mus musculus (Mouse) Q91VM5
TIB-55 BB88 cDNA, RIKEN full-length enriched library, clone:I730032G19 
product:RNA-binding protein FUS - Mus musculus (Mouse) Q3UK30|
Histone H4 - Mus musculus (Mouse) A0AUM5 50137141 174603342 1 : 3.48
17 days embryo kidney cDNA, RIKEN full-length enriched library, clone:I920097C16 
product:DEAH - Mus musculus (Mouse) Q3TF92|Q
TIB-55 BB88 cDNA, RIKEN full-length enriched library, clone:I730090E06 
product:ribosomal protein L5, full insert sequence. - Mus musculus (Mouse) Q3THE1|
Chromobox homolog 3 - Mus musculus (Mouse) Q32P00|Q
2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, 
clone:E430001A02 product:high mobility group box 2, full insert sequence - Mus 
musculus (Mouse) Q3U566|
NOD-derived CD11c +ve dendritic cells cDNA, RIKEN full-length enriched library, 
clone:F630119J17 product:MYB binding protein - Mus musculus (Mouse) Q3U2W2
Npm1 protein - Mus musculus (Mouse) Q5BL09|Q 4872664 6942082 1 : 1.43
Activated spleen cDNA, RIKEN full-length enriched library, clone:F830304D19 
product:polypyrimidine tract binding protein 1, full insert sequence - Mus musculus 
(Mouse) Q3T984|Q
Bone marrow macrophage cDNA, RIKEN full-length enriched library, clone:I830018I23
product:ribosomal protein L7, full insert sequence - Mus musculus (Mouse) Q3UBI6|Q
10 day old male pancreas cDNA, RIKEN full-length enriched library, 
clone:1810006O06 product:RNA binding motif protein 3, full insert sequence - Mus 
musculus (Mouse) Q545K5|Q
Bone marrow macrophage cDNA, RIKEN full-length enriched library, 
clone:I830085L15 product:splicing factor, arginine/serine-rich 3 - Mus musculus 
(Mouse) Q3U781|
Zfp326 protein - Mus musculus (Mouse) Q05DP5|
Bone marrow macrophage cDNA, RIKEN full-length enriched library, clone:I830080I04
product:ribosomal protein L26, full insert sequence - Mus musculus (Mouse) Q3U7N1|
10 days neonate cerebellum cDNA, RIKEN full-length enriched library, 
clone:6530441M19 product:U6 SNRNA-ASSOCIATED SM-LIKE PROTEIN LSM6 
homolog - Mus musculus (Mouse) Q542U7|
TIB-55 BB88 cDNA, RIKEN full-length enriched library, clone:I730091D16 
product:ribosomal protein L8, full insert sequence - Mus musculus (Mouse) Q3THC7
Eukaryotic translation elongation factor 1 delta - Mus musculus (Mouse) Q68FG5|
Novel protein silmilar to ribosomal protein L32 - Mus musculus (Mouse) A2AD25|A
Rps28 protein - Mus musculus (Mouse) Q059I1|Q
Bone marrow macrophage cDNA, RIKEN full-length enriched library, 
clone:I830030H04 product:H2A histone family, member Z, full insert sequence - Mus 
musculus (Mouse) Q3UA95|
Ribosomal protein S23 - Mus musculus (Mouse) Q497E1|Q
12 days embryo head cDNA, RIKEN full-length enriched library, clone:3010002H06 
product:small nuclear ribonucleoprotein polypeptide A, full insert sequence - Mus 
musculus (Mouse) Q9CXX7
60S ribosomal protein L13 - Mus musculus (Mouse) Q5RKP3
Adult male epididymis cDNA, RIKEN full-length enriched library, clone:9230011J09 
product:ribosomal protein L24, full insert sequence - Mus musculus (Mouse) Q3UW40
CRL-1722 L5178Y-R cDNA, RIKEN full-length enriched library, clone:I730071I06 
product:ribosomal protein 10, full insert sequence - Mus musculus (Mouse) Q3THJ6|
Osteoclast-like cell cDNA, RIKEN full-length enriched library, clone:I420048M08 
product:DEAD - Mus musculus (Mouse) Q3TVJ3|Q
Small nuclear ribonucleoprotein D2 - Mus musculus (Mouse) Q14AF6|
CRL-1722 L5178Y-R cDNA, RIKEN full-length enriched library, clone:I730023C04 
product:nascent polypeptide-associated complex alpha polypeptide, full insert 
sequence - Mus musculus (Mouse) Q3UK68|
Eukaryotic translation elongation factor 1 gamma - Mus musculus (Mouse) Q4FZK2|
12 days embryo head cDNA, RIKEN full-length enriched library, clone:3010025E17 
product:Heterogeneous nuclear ribonucleoprotein A0 - Mus musculus (Mouse) Q9CX86|
Ribosomal protein S13 - Mus musculus (Mouse) Q5BLJ7|Q
Ribosomal protein S6 - Mus musculus (Mouse) Q5BLK1|
Histone H2B - Mus musculus (Mouse) A0JLV3|A 40678518 78337773 1 : 1.93
Ribosomal protein L21 - Mus musculus (Mouse) Q4VA28|
Csda protein - Mus musculus (Mouse) Q68G78|
SET translocation - Mus musculus (Mouse) A2BE93|A
Cytochrome c, testis - Mus musculus (Mouse) A2ARH7|
Chromobox homolog 1 - Mus musculus (Mouse) A2A6C8|A
SMT3 suppressor of mif two 3 homolog 2 - Mus musculus (Mouse) A2A9X2|A
Retinoblastoma binding protein 4 - Mus musculus (Mouse) A2A875|A
RNA binding motif protein 17 - Mus musculus (Mouse) A2AP41|A
KH domain containing, RNA binding, signal transduction associated 1 - Mus musculus 
(Mouse) A2ACH3|
13 days embryo liver cDNA, RIKEN full-length enriched library, clone:2510005B08 
product:U6 snRNA-associated SM-like protein 4, full insert sequence - Mus musculus 
(Mouse) Q9CY46|
Muscle protein 684 - Mus musculus (Mouse) Q9QYY3
Osteoclast-like cell cDNA, RIKEN full-length enriched library, clone:I420007N06 
product:splicing factor, arginine/serine rich 9, full insert sequence - Mus musculus 
(Mouse) Q3TXM9
PBK1 - Mus musculus domesticus (western European house mouse) Q1PG84|
Copine III - Mus musculus (Mouse) A2AGJ0|A
17 days embryo heart cDNA, RIKEN full-length enriched library, clone:I920072D16 
product:actin, alpha, cardiac, full insert sequence - Mus musculus (Mouse) Q3UIJ3|Q
Table 2: Mass spectrometric  analysis of nulcear matrix fractions after sodium tetrathionate fixation
The number of peptide hits, accession number and the protein name is given  of each protein.
Protein name Acc. Nr. noDox Dox DIF
Bone marrow macrophage cDNA, RIKEN full-length enriched library, clone:G530123O18 
product:actinin alpha 4, full insert sequence - Mus musculus (Mouse)
Q3UDJ7|Q
8 18 10
Alpha actinin 1a - Mus musculus (Mouse) A1BN54|A 0 10 10
Nuclear factor 90 - Mus musculus (Mouse) Q45VK5|Q 5 12 7
nucleolin :: Blastocyst blastocyst cDNA, RIKEN full-length enriched library, clone:I1C0002A07 
product:nucleolin, full insert sequence - Mus musculus (Mouse) Q3TL52|Q
34 40 6
Bone marrow macrophage cDNA, RIKEN full-length enriched library, clone:I830119C09 
product:vimentin, full insert sequence - Mus musculus (Mouse) Q3U6S1|Q
8 14 6
5 days embryo whole body cDNA, RIKEN full-length enriched library, clone:I0C0047C10 
product:heterogeneous nuclear ribonucleoprotein K, full insert sequence - Mus musculus (Mouse)
Q3TL71|Q
5 11 6
importin a2 :: Karyopherin - Mus musculus (Mouse) Q52L97|Q 0 6 6
YB-1 :: Bone marrow macrophage cDNA, RIKEN full-length enriched library, clone:I830015L07 
product:nuclease sensitive element binding protein 1, full insert sequence - Mus musculus 
(Mouse) Q3UBT1|Q
3 8 5
Bone marrow macrophage cDNA, RIKEN full-length enriched library, clone:I830082P18 
product:ribosomal protein L15, full insert sequence - Mus musculus (Mouse)
Q3U7D2|Q
0 5 5
Heterogeneous nuclear ribonucleoprotein A3 - Mus musculus (Mouse) A2AL12|A2 0 5 5
Rpl17 protein - Mus musculus (Mouse) Q505B1|Q 0 5 5
CRL-1722 L5178Y-R cDNA, RIKEN full-length enriched library, clone:I730029B08 
product:heterogeneous nuclear ribonucleoprotein A1, full insert sequence - Mus musculus 
(Mouse) Q3TIK8|Q3
11 15 4
SAF-A :: Osteoclast-like cell cDNA, RIKEN full-length enriched library, clone:I420039N16 
product:heterogeneous nuclear ribonucleoprotein U, full insert sequence - Mus musculus (Mouse)
Q3TVV6|Q
3 7 4
Histone H2B - Mus musculus (Mouse) A0JLV3|A0 2 6 4
Ilf2 :: 12 days embryo female mullerian duct includes surrounding region cDNA, RIKEN full-length 
enriched library, clone:6820446H05 product:interleukin enhancer binding factor 2, full insert 
sequence - Mus musculus (Mouse) Q3UXI9|Q
2 6 4
Bone marrow macrophage cDNA, RIKEN full-length enriched library, clone:I830165N20 
product:ribosomal protein S3a, full insert sequence - Mus musculus (Mouse)
Q3U5P8|Q
2 6 4
12 days embryo female mullerian duct includes surrounding region cDNA, RIKEN full-length 
enriched library, clone:6820407G10 product:ribosomal protein S4, X-linked, full insert sequence - 
Mus musculus (Mouse) Q3UXQ6|Q
0 4 4
Rps16 protein - Mus musculus (Mouse) A4FUS1|A 0 4 4
importin a2 :: 17 days embryo stomach cDNA, RIKEN full-length enriched library, 
clone:I920087J04 product:karyopherin - Mus musculus (Mouse) Q3TFE8|Q
0 4 4
Hsp90aa1 protein - Mus musculus (Mouse) A0PJ91|A0 0 4 4
TIB-55 BB88 cDNA, RIKEN full-length enriched library, clone:I730090E06 product:ribosomal 
protein L5, full insert sequence - Mus musculus (Mouse) Q3THE1|Q
0 4 4
HuR; ELAV :: Adult pancreas islet cells cDNA, RIKEN full-length enriched library, 
clone:C820018E11 product:ELAV - Mus musculus (Mouse) Q3UFF9|Q
0 4 4
Bone marrow macrophage cDNA, RIKEN full-length enriched library, clone:I830046M23 
product:poly A binding protein, cytoplasmic 1, full insert sequence - Mus musculus (Mouse)
Q3U8U8|Q
19 22 3
Elongation factor 1-alpha - Mus musculus (Mouse) Q3TII3|Q3 7 10 3
Bone marrow macrophage cDNA, RIKEN full-length enriched library, clone:I830120C02 
product:heterogeneous nuclear ribonucleoprotein C, full insert sequence - Mus musculus (Mouse)
Q3U6P5|Q
6 9 3
Activated spleen cDNA, RIKEN full-length enriched library, clone:F830304D19 
product:polypyrimidine tract binding protein 1, full insert sequence - Mus musculus (Mouse)
Q3T984|Q
3 6 3
Heterogeneous nuclear ribonucleoprotein H1 - Mus musculus (Mouse) Q811L7|Q 2 5 3
ras associated endonuclease G3Bp :: MKIAA4115 protein - Mus musculus (Mouse) Q571F9|Q 0 3 3
La :: 17 days pregnant adult female amnion cDNA, RIKEN full-length enriched library, 
clone:I920058I09 product:Sjogren syndrome antigen B, full insert sequence - Mus musculus 
(Mouse) Q3TG93|Q
0 3 3
CRL-1722 L5178Y-R cDNA, RIKEN full-length enriched library, clone:I730023C04 
product:nascent polypeptide-associated complex alpha polypeptide, full insert sequence - Mus 
musculus (Mouse) Q3UK68|Q
0 3 3
Osteoclast-like cell cDNA, RIKEN full-length enriched library, clone:I420032B10 product:ribosomal 
protein S18, full insert sequence - Mus musculus (Mouse) Q3TW65|Q
0 3 3
In vitro fertilized eggs cDNA, RIKEN full-length enriched library, clone:7420408C23 
product:heterogeneous nuclear ribonucleoprotein D, full insert sequence - Mus musculus (Mouse)
Q3UXC8|Q
0 3 3
PCNA :: 2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, 
clone:E430008I01 product:proliferating cell nuclear antigen, full insert sequence - Mus musculus 
(Mouse) Q542J9|Q5
0 3 3
Bone marrow macrophage cDNA, RIKEN full-length enriched library, clone:I830045N07 
product:heterogeneous nuclear ribonucleoprotein R, full insert sequence - Mus musculus (Mouse)
Q3U8W9|Q
0 3 3
Ribosomal protein S14 - Mus musculus (Mouse) O70569|O 0 3 3
Eukaryotic translation elongation factor 1 gamma - Mus musculus (Mouse) Q4FZK2|Q 0 3 3
Histone cluster 1, H1d - Mus musculus (Mouse) Q149Z9|Q 0 3 3
Tarbp :: 3 days neonate thymus cDNA, RIKEN full-length enriched library, clone:A630098I22 
product:TAR DNA binding protein, full insert sequence - Mus musculus (Mouse)
Q3U591|Q
0 3 3
Histone H3 - Mus musculus (Mouse) A1L0U3|A 0 3 3
Tpr/Mlp1/Mlp2/megator :: Nuclear pore complex-associated intranuclear coiled-coil protein TPR - 
Mus musculus (Mouse) Q7M739|Q
11 13 2
S1 protein C2 - Mus musculus (Mouse) Q20BD0|Q 8 10 2
14-3-3 :: Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon 
polypeptide - Mus musculus (Mouse) Q5SS40|Q
5 7 2
60S acidic ribosomal protein P0 - Mus musculus (Mouse) Q5FWB6|Q 4 6 2
Peptidyl-prolyl cis-trans isomerase - Mus musculus (Mouse) Q3TE63|Q 3 5 2
LOC665931 protein - Mus musculus (Mouse) Q7TNQ6|Q 3 5 2
Histone H2A - Mus musculus (Mouse) A0AUV1|A 2 4 2
Ribosomal protein S13 - Mus musculus (Mouse) Q5BLJ7|Q 0 2 2
Ribosomal protein L9 - Mus musculus (Mouse) Q5EBQ6|Q 0 2 2
Ribosomal protein L19 - Mus musculus (Mouse) A2A547|A2 0 2 2
Ribosomal protein S21 - Mus musculus (Mouse) A2ABW8|A 0 2 2
2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:E430001E01 
product:ribosomal protein L10A, full insert sequence - Mus musculus (Mouse)
Q3U561|Q
0 2 2
CRL-1722 L5178Y-R cDNA, RIKEN full-length enriched library, clone:I730056L04 
product:ribosomal protein L8, full insert sequence - Mus musculus (Mouse) Q3UJS0|Q
0 2 2
Activated spleen cDNA, RIKEN full-length enriched library, clone:F830112M22 product:ribosomal 
protein L3, full insert sequence - Mus musculus (Mouse) Q3T9U9|Q
0 2 2
Thioredoxin 1 - Mus musculus (Mouse) A2AV97|A 0 2 2
Ribosomal protein S20 - Mus musculus (Mouse) Q5BLK2|Q 0 2 2
Ribosomal protein S23 - Mus musculus (Mouse) Q497E1|Q 0 2 2
BAF53  :: cDNA, RIKEN full-length enriched library, clone:I920165I07 product:53 kDa BRG1-
associated factor A - Mus musculus (Mouse) Q3TF62|Q
0 2 2
Bone marrow macrophage cDNA, RIKEN full-length enriched library, clone:I830018I23 
product:ribosomal protein L7, full insert sequence - Mus musculus (Mouse)
Q3UBI6|Q
0 2 2
40S ribosomal protein S24 - Mus musculus (Mouse) Q3TIF8|Q3 0 2 2
Rplp1 protein - Mus musculus (Mouse) Q58E35|Q 0 2 2
Ribosomal protein L38 - Mus musculus (Mouse) Q52KP0|Q 0 2 2
cDNA, RIKEN full-length enriched library, clone:I920161F21 product:poly(rC) binding protein 2, full 
insert sequence - Mus musculus (Mouse) Q3TF69|Q
0 2 2
Ribosomal protein S26 - Mus musculus (Mouse) Q497N1|Q 0 2 2
CRL-1722 L5178Y-R cDNA, RIKEN full-length enriched library, clone:I730073G06 product:60S 
ribosomal protein L18a, full insert sequence - Mus musculus (Mouse) Q3THJ0|Q
0 2 2
Peroxiredoxin 1 - Mus musculus (Mouse) B1AXW5|B 9 10 1
Blastocyst blastocyst cDNA, RIKEN full-length enriched library, clone:I1C0038L22 
product:eukaryotic translation elongation factor 2, full insert sequence - Mus musculus (Mouse)
Q3TK17|Q
5 6 1
10 day old male pancreas cDNA, RIKEN full-length enriched library, clone:1810006O06 
product:RNA binding motif protein 3, full insert sequence - Mus musculus (Mouse)
Q545K5|Q
4 5 1
Histone H4 - Mus musculus (Mouse) Q61667|Q 3 4 1
60S ribosomal protein L6 - Mus musculus (Mouse) Q3UCH0|Q 3 4 1
Ribosomal protein S8 - Mus musculus (Mouse) Q497E9|Q 3 4 1
14-3-3 protein gamma subtype - Mus musculus (Mouse) A8IP69|A8 2 3 1
Splicing factor, arginine/serine-rich 2 - Mus musculus (Mouse) A2AA29|A 2 3 1
Rps9 protein - Mus musculus (Mouse) Q96EC0|Q 2 3 1
Blastocyst blastocyst cDNA, RIKEN full-length enriched library, clone:I1C0007H08 
product:ribosomal protein S2, full insert sequence - Mus musculus (Mouse) Q3TL20|Q
2 3 1
Bone marrow macrophage cDNA, RIKEN full-length enriched library, clone:I830164A20 
product:actin, beta, cytoplasmic, full insert sequence - Mus musculus (Mouse) Q3U5R4|Q
15 15 0
Bone marrow macrophage cDNA, RIKEN full-length enriched library, clone:I830008E12 
product:ribosomal protein S3, full insert sequence - Mus musculus (Mouse)
Q3UCL7|Q
7 7 0
Poly A binding protein, cytoplasmic 4 - Mus musculus (Mouse) A3KFU5|A 5 5 0
2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:E430010B17 
product:ribosomal protein L4, cytosolic homolog - Mus musculus (Mouse)
Q564E8|Q
4 4 0
TIB-55 BB88 cDNA, RIKEN full-length enriched library, clone:I730008D20 product:ribosomal 
protein L12, full insert sequence - Mus musculus (Mouse) Q3TIQ2|Q
3 3 0
Chromobox homolog 3 - Mus musculus (Mouse) Q2YD72|Q 3 3 0
Bone marrow macrophage cDNA, RIKEN full-length enriched library, clone:I830034K17 
product:ribosomal protein S10, full insert sequence - Mus musculus (Mouse)
Q3U9P0|Q
2 2 0
Ribosomal protein L18 - Mus musculus (Mouse) Q0QEW9|Q 3 3 0
Ribosomal protein L7a - Mus musculus (Mouse) Q58ET1|Q 3 3 0
Rpl23a protein - Mus musculus (Mouse) Q4V9X9|Q 3 3 0
Rps28 protein - Mus musculus (Mouse) Q059I1|Q0 2 2 0
Ribosomal protein S6 - Mus musculus (Mouse) Q5BLK1|Q 2 2 0
13 days embryo head cDNA, RIKEN full-length enriched library, clone:3110001F06 product:cofilin 
1, non-muscle, full insert sequence - Mus musculus (Mouse) Q544Y7|Q
2 2 0
Ribosomal protein S15a - Mus musculus (Mouse) Q5M9M4|Q 2 2 0
Rbmxrt protein - Mus musculus (Mouse) Q91VM5|Q 2 2 0
Ribosomal protein L23 - Mus musculus (Mouse) A2A6F9|A2 2 2 0
ES cells cDNA, RIKEN full-length enriched library, clone:2410026P17 product:ribosomal protein 
L14, cytosolic homolog - Mus musculus (Mouse) Q9CWK0|Q
2 2 0
Adult male epididymis cDNA, RIKEN full-length enriched library, clone:9230011J09 
product:ribosomal protein L24, full insert sequence - Mus musculus (Mouse) Q3UW40|Q
2 2 0
Activated spleen cDNA, RIKEN full-length enriched library, clone:F830208A11 product:DEAD - 
Mus musculus (Mouse) Q3T9L0|Q
2 2 0
Ribosomal protein L31 - Mus musculus (Mouse) Q5M9K9|Q 2 2 0
Ribosomal protein L26 - Mus musculus (Mouse) B1ARA3|B 2 2 0
Tpm3 protein - Mus musculus (Mouse) Q58E70|Q 13 12 -1
AHNAK - Mus musculus (Mouse) Q6UL10|Q 7 6 -1
Npm1 protein - Mus musculus (Mouse) Q5BL09|Q 8 7 -1
60S ribosomal protein L13 - Mus musculus (Mouse) Q5RKP3|Q 4 3 -1
Adult male liver tumor cDNA, RIKEN full-length enriched library, clone:C730027A09 
product:Hypothetical RNA binding protein RDA288 homolog, full insert sequence - Mus musculus 
(Mouse) Q3UEI6|Q
3 2 -1
Ribosomal protein S25 - Mus musculus (Mouse) Q58EA6|Q 3 2 -1
10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:6530441M19 
product:U6 SNRNA-ASSOCIATED SM-LIKE PROTEIN LSM6 homolog - Mus musculus (Mouse)
Q542U7|Q
3 2 -1
15 days pregnant adult female placenta cDNA, RIKEN full-length enriched library, 
clone:I530024D06 product:annexin A7, full insert sequence - Mus musculus (Mouse) Q3TJ49|Q
3 2 -1
Tcof1 protein - Mus musculus (Mouse) Q05CS0|Q 7 5 -2
13 days embryo liver cDNA, RIKEN full-length enriched library, clone:2510005B08 product:U6 
snRNA-associated SM-like protein 4, full insert sequence - Mus musculus (Mouse)
Q9CY46|Q
4 2 -2
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta polypeptide - 
Mus musculus (Mouse) A3KML3|A
2 0 -2
Ribosomal protein L11 - Mus musculus (Mouse) A2BH07|A 2 0 -2
Osteoclast-like cell cDNA, RIKEN full-length enriched library, clone:I420031E23 product:heat 
shock protein, A, full insert sequence - Mus musculus (Mouse) Q3TW93|Q
2 0 -2
CRL-1722 L5178Y-R cDNA, RIKEN full-length enriched library, clone:I730064N19 
product:guanine nucleotide binding protein, beta 2, related sequence 1, full insert sequence - Mus 
musculus (Mouse) Q3THP0|Q
2 0 -2
Retinoblastoma binding protein 4 - Mus musculus (Mouse) A2A875|A2 2 0 -2
17 days pregnant adult female amnion cDNA, RIKEN full-length enriched library, 
clone:I920090G16 product:Moloney leukemia virus 10, full insert sequence - Mus musculus 
(Mouse) Q3TFC0|Q
2 0 -2
Rps19 protein - Mus musculus (Mouse) Q5M9P3|Q 3 0 -3
MKIAA0670 protein - Mus musculus (Mouse) Q80TU6|Q 3 0 -3
40S ribosomal protein S12 - Mus musculus (Mouse) Q6ZWZ6|Q 4 0 -4
Muscle protein 684 - Mus musculus (Mouse) Q9QYY3|Q 4 0 -4
2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library, clone:E430001E13 
product:heat shock protein 8, full insert sequence - Mus musculus (Mouse)
Q3TEK2|Q
20 15 -5
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Discussion 
 
Early in ES differentiation, Xist spreads over the length of the X chromosome 
from which it is transcribed and transcriptionally silences the whole chromosome. 
The formation of this Xist covered chromosome territory is not sufficient for gene 
repression. Thus far, the mechanism and the factors that cooperate with Xist the 
initiation of gene silencing are presently unknown. 
Here we established a protocol that allows to isolate defined nuclear 
fractions and to compare its protein content with and without Xist expression. We 
predicted to identify factors involved in the initiation of X chromosome inactivation 
in an unbiased manner by protein analysis of the Xist containing cell fraction. We 
established a biochemical fractionation procedure of the nuclear matrix fraction to 
detect proteins that become enriched upon X inactivation. Using this method 
followed by mass spectrometric analysis of protein samples we identified an 
enrichment of Trim28 in ES cells upon Xist expression among other candidates. 
Trim28 is especially interesting as it has been implicated in retroviral silencing in 
ES cells (Wolf and Goff, 2007). We confirmed our results by Western analysis 
suggesting an enrichment of Trim28 in the nuclear matrix, which is triggered by 
Xist expression in undifferentiated ES cells. It remains unclear if Trim28 is acting 
in gene silencing on the inactive X chromosome. This question could be 
addressed by expressing a silencing defective version of Xist that lacks the A-
repeat. Genetic testing for a function of Trim28 in gene silencing by Xist is 
difficult as ES cells deficient in Trim28 have not yet been established. 
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Recruitment of Trim28 to the inactive X chromosome should further be 
investigated using immunofluorescence analysis. Colocalization of Trim28 with 
Xist could give further support to a role of Trim28 in X inactivation and would 
provide a potential link to antiviral host defence mechanisms. 
 Our method is suitable to be combined with advanced mass spectrometric 
measurements. Precise quantisation of protein amounts in nuclear fractions can 
be achieved using isotypic labelling of the samples with and without Xist 
induction. Approaches including SILAC will enable to characterize the changes in 
the chromosomal protein composition, which is triggered by Xist. This can 
potentially lead to the identification of factors that are crucial for Xist RNA 
localization, gene silencing and also maintenance of X inactivation. Albeit, an 
ever increasing number of factors are being identified, key components for 
explaining the mechanism of X inactivation are still missing. Direct biochemical 
approaches promise to fill in this missing information and advance our 
understanding of dosage compensation in mammals 
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Material and Methods 
 
Cell culture of mouse ES cells  
 
Media 
 
MEFS (mouse embryonic feeder) medium 
450ml DMEM 
50ml (10%) FCS 
 5ml L-Glutamnine (Sigma) 
5ml non-essential amino acids (GIBCO) 
5ml sodium pyruvate (sigma) 
5ml penicillin streptomycin solution (GIBCO) 
4µl ß-mercaptoethanol 
 
filtered through Nalgene filter (pore size 0,2µm)  and stored at 4°C 
 
ES-medium 
450ml DMEM 
75ml (15%) FCS 
 5ml L-Glutamnine (Sigma) 
5ml non-essential amino acids (GIBCO) 
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5ml sodium pyruvate (sigma) 
5ml penicillin streptomycin solution (GIBCO) 
4µl ß-mercaptoethanol 
250µl LIF (500 Units/ml, leukemia inhibitory factor) 
filtered through Nalgene filter (pore size 0,2µm)  and stored at 4°C 
 
Retinoic acid differentiation (RADIF) - medium 
450ml DMEM 
75ml (15%) FCS 
 5ml L-Glutamnine (Sigma) 
5ml non-essential amino acids (GIBCO) 
5ml sodium pyruvate (sigma) 
5ml penicillin streptomycin solution (GIBCO) 
4µl ß-mercaptoethanol 
2µl retinoic acid  
filtered through Nalgene filter (pore size 0,2µm)  and stored at 4°C 
 
ES cells were cultured in DMEM in the presence of 15% fetal calf serum (PAA, 
Austria), and 250 U of LIF/ml as described previously (Wutz and Jaenisch, 2000). 
Cultures were grown on mitotically inactivated mouse embryonic fibroblast feeder 
cells and passages every 3 days. Cells were rinsed twice with PBS (Ca Mg free) 
and then dissociated by treatment with 0.25% trypsin for 5 minutes at 37°C. 
Established ES cell lines were permanently stored in liquid nitrogen in cryotubes 
by adding 2xfreezing medium (20% DMSO; 80% fetal calf serum). For 
biochemical preparations ES cell cultures were cultured for 2 days on gelatine 
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(2%) coated plates without feeder cells. Xist was induced by the addition of 
1µg/ml doxycycline (Sigma). Differentiating ES cells were cultured in DMEM 
containing 10% fetal calf serum (PAA, Austria) and differentiation was induced 
with 100nM all-trans-retinoic acid (Sigma). 
 
 
Immunofluorescence staining 
 
For immunofluorescence ES cells were grown on Roboz slides (CellPoint 
Scientific, Gaithersburg, Maryland, United States) over night. The following steps 
were performed at RT. Briefly, cells were washed in PBS, fixed for 10 minutes in 
4% PFA in PBS and permeabilzed for 5 minutes in 0,1% Na Citrate/ 0,1% Triton-
X100 in water. Subsequently, cells were rinsed with PBS and blocked for 30 
minutes in PBS containing 5% (wt/vol) BSA, 0,1% Tween-20. Thereafter cells 
were incubated for 2 hours with the primary antibody diluted in blocking solution, 
washed 3 times for 5 minutes with PBS containing 0,1% Tween and incubated 
for 1 hour with the secondary antibody, which was diluted 1:500 with blocking 
solution. Finally, cells were washed 2 times for 5 minutes with PBS containing 
0,1% Tween, 5 minutes with PBS, incubated with PBS containing DAPI and 
mounted. 
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The following antibodies were used: 
 
- Rabbit Sir2  (GeneTex, GTX12193) 
dilution: 1:50 
- Rabbit Sirt1 (delta biolabs, C19) 
dilution: 1:50 
- Goat Sirt1 (Santa Cruz Biotechnology, sc-19857) 
dilution: 1:50 
- Rabbit Sirt1 (Santa Cruz Biotechnology, sc-15404) 
dilution: 1:50 
- Rabbit Anti Sir2 (Sigma, S 5313) 
dilution: 1: 50  
- Rabbit Sirt1 (abcam, ab12193) 
dilution: 1:50 
- Rabbit Sirt1 (abccam, ab28170) 
dilution: 1:50 
- Goat Sirt1 (abcam, ab53517) 
dilution: 1:50 
- Rabbit Ash2 (bethyl, A300-107A) 
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Xist fluorescence in situ hybridization 
Hybridizationbuffer 
1 part 20x SSC 
2 parts 10mg/ml BSA 
2 parts 50% dextran sulphate 
Mixed and stored at -20°C 
 
Cytoskeletal buffer 
20ml 5M NaCl 
102,7g sucrose 
3ml 1M MgCl2 
10ml Pipes pH 6,8 
to 1l with H2O 
 
Generation of Xist RNA FISH probe 
 
Xist RNA FISH probes were generated by random priming (Stratagene, La Jolla, 
Califorinia, United States) using Cy3-dCTP (Amersham). 100ng/µl of 
PGK∆XistPA was mixed with 22µl H2O, and 10µl random primer, denatured for 5 
minutes at 95°C and cooled on ice. Thereafter 10µl CTP-buffer, 0,5µl Cy3-dCTP 
and 1µl Klenow enzyme were added. The reaction mixture was incubated over 
night at 37°C. After stopping the reaction with 2µl EDTA (0,5M, pH 8), RNA 
fragments between 100 bp and 10 kb in length were purified using the QIAquick 
PCR Purification Kit. As final purification step, the probe was harvested in 30µl 
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TE-buffer and centrifuged for 5 minutes at 900rpm and 4°C. Subsequently, the 
probe was diluted in 20µl tRNA (20mg/ml), 20µl salmon sperm DNA (10mg/ml), 
13µl (1/10V) 3M NaAc (pH 5,2) and 2,5V ethanol (absolute) and precipitated at -
20°C over night. After centrifuging the probe at 13krpm, the pellet was washed 
twice with ethanol (absolute) and centrifuged for 5 minutes at 13krpm. The dry 
pellet was diluted in 80µl hybridization buffer, put for 10 mintues at 72°C, for 30 
minutes at 37°C and stored at -20°C. 
 
Probe hybridization  
 
Cells were grown on robozslides, rinsed with PBS, extracted for 2 minutes with 
cytoskeletal buffer, rinsed with PBS and fixed for 10 minutes with 4% PFA. After 
cells were rinsed with 70% ethanol, several washing steps each for 5 minutes 
were performed: Cells were incubated in 70% ethanol, in 80% ethanol, in 95% 
ethanol and finally in 100% ethanol. Dry cells were hybridized over night at 37°C 
in a dark humid chamber with 4µl probe. Cells were washed in an agitating water 
bath at 37°C for 5 minutes 3 times with 2x SSC/ 50% formamide, for 5 minutes 3 
times with 2x SSC, for 10 minutes with 1xSSC. Subsequently cells were washed 
for 5 minutes at room temperature with 4x SSC, stained for 5 minutes with 4x 
SSC + DAPI, washed for  5 minutes with 4x SSC and mounted. 
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SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and 
Western blot analysis 
 
Buffers and Solutions 
 
4x TrisCl/SDS pH 6,8 (0,5M Tris.Cl, 0,4 % SDS) 
6,05g Tris base 
40ml H2O 
pH 6,8 with 1M HCl 
H2O to 100ml total V 
2ml 20% SDS 
filter through 0,45µm filter 
 
4x Tris.Cl/SDS pH 8,8 (1,5M Tris.Cl, 0,4% SDS) 
91g Tris base in 300ml H2O 
pH to 8,8 with 1M HCl 
add 10ml 20% SDS 
H2O to 500ml  
filter through 0,45µm filter 
 
5x Tris- gly electrophoresis buffer 
25ml 20% SDS 
15,1 Tris base 
72g glycine 
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Poneau solution 
0,2% Ponceau 
5% acetic acid 
 
20x Transfer buffer 
58,6 glycine 
116,2 g Tris base 
37,5 ml 20% SDS 
H2O to 1l 
 
1x Transfer buffer 
50ml 20x transfer buffer 
200ml methanol 
750ml H2O 
 
We prepared 9% of polyacrylamide gel for all protein analysis. The separating gel 
was poured, with isopropanol and polymerized. Then the isopropanol was 
removed and the stacking gel was added on the top of the separating gel. Protein 
samples were mixed with 6x loading buffer, boiled for 3 minutes at 95°C, spinned 
down and loaded into the wells. The protein amount according to nuclear matrix 
extraction analysis was always 1/10 of total sample. After running the gel at 
25mA, the proteins were transferred over night at 4°C and 300mA using a 
stirrerto a nitrocellulose membrane. The blot was incubated in a poceau solution 
for some minutes and washed with PBS to test the protein transfer. Blocking was 
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performed for 30 minutes in an appropriate blocking solution (see usage of 
antibodies) and the first antibody was incubated for 2 hours in blocking solution. 
Washing steps and antibody incubations was performed in rolling falcon tubes. 
The membrane was washed 3 times for 5 minutes with PBS, 0,1% Tween and 
subsequently incubated for 1 hour with the secondary antibody (diltution: 1:10 
000), horse raddish peroxidise coupled. The membrane was washed 3 times for 
5 minutes with PBS, 0,1% Tween, rinsed with PBS, incubated for 1 minute with 
ECL detection solution and put in a plastic folder. Finally, the membrane was 
exposed for different times (starting with 5 seconds) to a luminescence sensitive 
film. The membranes were stored at -20°C. 
 
 The following antibodies were used: 
- Rabbit Kap-1 (Trim28) Antibody (300 274A; Bethyl) 
blocking: 5% BSA, 0,1% Tween in PBS 
dilution: 1:10 000  
- Rabbit polyclonal hnRNP U Antibody (ab20666, abcam) 
blocking: 3% milk powder, 0,1% Tween in PBS 
dilution: 0,4µg/µl 
- Rabbit polyclonal to Histone H3 (ab1791, abcam) 
blocking: 5% BSA, 0,1% Tween in PBS 
dilution: 1:5000 
- Rabbit Ash2 Antibody (A300-107A, Bethyl) 
blocking: 5% BSA, 0,1% Tween in PBS 
dilution: 1:10 000 
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 Nuclear Matrix extraction 
 
Buffers and Solutions 
 
Nuclei isolation (NI) Stock 
100mM Tris/HCl pH 7,4 
10mM MgCl2 
10mM CaCl2 
2% NP40 
1,6% Triton X100 
 
Nuclei isolation (NI) buffer (prepared fresh before use) 
1,6 ml NI-stock 
0,4 ml Ficoll-Paque 
2 µl 1M DMSO  
1 mM 1M PMSF 
 
PRE – NI stock 
100 mM Tris/HCl pH7,4 
10 mM CaCl2 
10 mM MgCl2 
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PRE – NI buffer 
1,6 ml PRE - NI-stock 
0,4 Ficoll Paque 
 
DNase I buffer 
10mM PIPES pH6,8, 300mM sucrose, 50mM NaCl, 3mM MgCl2, 0,5% 
Triton X-100, 1mM CaCl2 
 
RNaseA buffer 
10mM Tris pH 7,0, 50mM NaCl, 3mM MgCl2 
 
Nuclei isolation 
ES cells were cultivated with feeder cells, splitted and grown for 2 days to 90 – 
95% confluency (2x107 cells) in a gelatine (2%) coated t75 flask without feeder 
cells. Cells were washed twice with PBS, trypsinized at 37°C 2-3 minutes with 1,5 
ml trypsin and mixed with 15ml medium. Subsequently cells are centrifuged for 5 
minutes at 900rcf, washed with PBS and diluted in 1ml medium. The following 
steps were performed at 4°C. Cells were overlaid onto 2ml cushion, centrifuged 
with increasing speed from 400rpm to 800rpm (30s/400rpm, 30s/500rpm, 
30s/600rpm, 30s/700rpm, 6min/800rpm), and slowed down using the brake 
(Haraeus 2.0R Megafuge).  
 
Nuclear Matrix extraction of unfixed nuclei (continue with isolated nuclei) 
Nuclei were washed in DNase buffer, centrifuged for 5 minutes at 0,2 rcf. The 
nuclear pellet was resuspended in 100µl DNA buffer containing 10 Units DNAseI 
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(RNAse-free; Fermentas) and 1µl RNasin. DNA digestion was performed for 1 hour 
at 32°C. Subsequently, chromatin was extracted for 5 minutes on ice by the 
addition of 33,3 µl 1M ammonium sulphate to obtain a final concentration of 250mM 
ammonium sulphate. The samples were centrifuged for 5 minutes at 0,4g. The 
supernatant of the extraction with ammonium sulphate was stored for further 
analysis. The remaining pellet was resuspended in 200µl RNase buffer containing 
9,6 µl RNase. RNA digestion was performed for 30 minutes at 4°C. The sample 
was centrifuged for 15 minutes at 4°C at 13krpm. The RNAse soluble supernatant 
and the insoluble pellet were stored at -20°C.   
 
Nuclear Matrix extraction of fixed nuclei (continue with isolated nuclei) 
Nuclei were resuspended in 700µl PRE-NI-buffer containing 1,4 µl 1M sodium 
tetrathionate (0,2mM total). After 1 minute, nuclei were centrifuged for 5 minutes at 
0,2 g and washed with 1 ml DNase buffer. The sample was resuspended in 100 µl 
DNAse buffer containing 10 Units DNAse I (RNAse free, Fermentas) and 1µl 
RNAse inhibitor. DNA digestion was performed for 1 hour at 32°C. Subsequently, 
the chromatin was digested for 5 minutes at 4°C by the addition of 33,3 µl 1M 
ammonium sulphate (final c: 250mM ammonium sulphate). The sample was 
centrifuged for 5 minutes at 2g and washed with 1ml RNAse buffer (centrifugation: 
5minutes, 2g). The pellet was digested for 30 minutes on ice with 9,6µg RNAse in 
200µl RNAse buffer. Finally, 12µl 1M DTT (total c: 60mM) were added to the 
reaction mixture and incubated for another 15 minutes. The sample was centrifuged 
for 15 minutes at 4°C and the soluble fraction and the insoluble pellet was stored at 
-20°C. 
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